Animal Drug and Animal Generic Drug User Fee Amendments of 2018

Bill: 115-hr-5554
Sponsor: full_name: Rep. Mullin, Markwayne [R-OK-2]
Introduced: 2018-04-18
Policy area: Health
Subjects: Appropriations

Congressional oversight

Department of Health and Human Services

Drug safety, medical device, and laboratory regulation

Executive agency funding and structure

Food and Drug Administration (FDA)

Food supply, safety, and labeling

Government information and archives

User charges and fees

Veterinary medicine and animal diseases
Latest action: action_date: 2018-08-14
text: Became Public Law No: 115-234.

Summaries:
action_date: 2018-08-14
action_desc: Public Law
text: <p><b>Animal Drug and Animal Generic Drug User Fee Amendments of 2018</b></p> <p>TITLE I--FEES RELATING TO ANIMAL DRUGS</p> <p>This bill addresses the authority of the Food and Drug Administration (FDA)to collect new animal drug (brand name animal drug)and generic animal drug user fees.</p> <p><i>Animal Drug User Fee Amendments of 2018</i></p> <p>(Sec.103)The bill amends the Federal Food, Drug, and Cosmetic Act to reauthorize through FY2023 the authority of the FDA to collect and use brand name animal drug user fees. </p> <p>The FDA must not collect fees for (1) supplemental applications that are submitted solely to add the animal drug application number to the label of the drug, and (2) applications for genetically engineered animals that are intended to produce human medical products. </p> <p>The bill revises the total amount of revenue brand name animal drug user fees can generate. </p>  <p>The bill also revises the requirements for calculating adjustments to revenue amounts based on changes in the workload for reviewing brand name animal drug applications.</p> <p>(Sec.104)The bill extends requirements for the FDA to report to Congress on achieving goals related to the animal drug development and review processes and implementation of the authority to collect brand name animal drug user fees. </p> <p>(Sec.107)The bill terminates the authority of the FDA to collect brand name animal drug user fees on October 1, 2023. </p> <p>TITLE II--FEES RELATING TO GENERIC ANIMAL DRUGS</p> <p><i>Animal Generic Drug User Fee Amendments of 2018</i></p> <p>(Sec.202)The bill reauthorizes through FY2023 the authority of the FDA to collect and use generic animal drug user fees.The FDA must not collect fees for supplemental abbreviated applications that are submitted solely to add the generic animal drug application number to the label of the drug.</p> <p> The bill revises the total amount of revenue each type of generic animal drug user fee must generate. </p> <p>The bill also revises the requirements for calculating adjustments to revenue amounts based on changes in the workload for reviewing generic animal drug applications.</p> <p>(Sec.203)The bill extends requirements for the FDA to report to Congress on achieving goals related to the generic animal drug development and review process and the implementation of the authority to collect generic animal drug fees. </p> <p>(Sec.206)The bill terminates the authority of the FDA to collect generic animal drug user fees on October 1, 2023. </p> <p>TITLE III--MISCELLANEOUS PROVISIONS</p> <p>(Sec.301)Brand name and generic animal drug applications must be submitted electronically beginning in FY2019. Additionally, applications for conditional approval of brand name animal drugs for minor use and minor species must be submitted electronically beginning in FY2019. (Minor use drugs are for intended uses in major species [horses, dogs, cats, cattle, pigs, turkeys, and chickens] for diseases that occur infrequently or in limited geographic areas and in only a small number of animals annually.)</p> <p>(Sec.302)Product labeling for certain unapproved brand name animal drugs for minor species must include the index number in order to be marketed.</p> <p>(Sec.303)The bill prohibits the sale of brand name animal drugs that do not include the FDA application number.</p> <p>(Sec.304)The bill authorizes the FDA to grant conditional approval of a brand name animal drug not intended for a minor use or minor species if (1) the drug is intended to treat a serious or life-threatening disease or condition or addresses an unmet animal or human health need, and (2) the FDA determines that a demonstration of effectiveness of the drug would require a complex or particularly difficult study or studies. </p> <p>The FDA must issue guidance or regulations that provide further details regarding the criteria for conditional approval. </p> <p>The bill terminates this conditional approval authority on October 1, 2028.</p> <p>The Government Accountability Office must study the effects of the conditional approval pathway for brand name animal drugs. </p> <p>(Sec.305)The FDA must issue guidance on how to evaluate certain elements of investigations as part of the animal drug application process, and how drug sponsors may obtain feedback from the agency on technical issues before submitting an application. </p> <p>(Sec.306)The FDA must review investigations conducted in foreign countries when acting on a petition for a food additive intended for use in animal food. </p> <p>The FDA must also issue guidance on the voluntary pre-petition consultation process for such food additives.</p>

tv_txt: I One Hundred Fifteenth Congress of the United States of America At the Second Session Begun and held at the City of Washington on Wednesday, the third day of January, two thousand and eighteen H. R. 5554 AN ACT To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.

1. Short title This Act may be cited as the Animal Drug and Animal Generic Drug User Fee Amendments of 2018 . 2. Table of contents; references in Act (a) Table of contents The table of contents for this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents; references in Act. Title I—Fees Relating to Animal Drugs Sec. 101. Short title; finding. Sec. 102. Definitions. Sec. 103. Authority to assess and use animal drug fees. Sec. 104. Reauthorization; reporting requirements. Sec. 105. Savings clause. Sec. 106. Effective date. Sec. 107. Sunset dates. Title II—Fees Relating to Generic Animal Drugs Sec. 201. Short title; finding. Sec. 202. Authority to assess and use generic new animal drug fees. Sec. 203. Reauthorization; reporting requirements. Sec. 204. Savings clause. Sec. 205. Effective date. Sec. 206. Sunset dates. Title III—Miscellaneous Provisions Sec. 301. Electronic submissions. Sec. 302. Index of legally marketed unapproved new animal drugs for minor species. Sec. 303. Misbranded drugs and devices. Sec. 304. Conditional approval of new animal drugs. Sec. 305. Guidance addressing investigation designs. Sec. 306. Food additives intended for use in animal food. (b) References in Act Except as otherwise specified, amendments made by this Act to a section or other provision of law are amendments to such section or other provision of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq.). I Fees Relating to Animal Drugs 101. Short title; finding (a) Short title This title may be cited as the Animal Drug User Fee Amendments of 2018 . (b) Finding Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the animal drug development process and the review of new and supplemental animal drug applications and investigational animal drug submissions as set forth in the goals identified for purposes of part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate as set forth in the Congressional Record. 102. Definitions Section 739 ( 21 U.S.C. 379j–11 ) is amended— (1) by amending paragraph (1) to read as follows: (1) (A) The term animal drug application means— (i) an application for approval of any new animal drug submitted under section 512(b)(1); or (ii) an application for conditional approval of a new animal drug submitted under section 571. (B) Such term does not include either a new animal drug application submitted under section 512(b)(2) or a supplemental animal drug application. ; and (2) in paragraph (8), by adding at the end the following: (I) The activities necessary for implementation of the United States and European Union Good Manufacturing Practice Mutual Inspection Agreement with respect to animal drug products subject to review, including implementation activities prior to and following product approval. . 103. Authority to assess and use animal drug fees (a) Fee revenue amounts Section 740(b) ( 21 U.S.C. 379j–12(b) ) is amended— (1) in paragraph (1)— (A) in subparagraph (A)— (i) by striking 2014 and inserting 2019 ; and (ii) by striking $23,600,000 and inserting $30,331,240 ; and (B) in subparagraph (B)— (i) by striking 2015 through 2018 and inserting 2020 through 2023 ; and (ii) by striking $21,600,000 and inserting $29,931,240 ; and (2) in paragraph (2), in the matter preceding subparagraph (A), by striking determined and inserting established . (b) Annual fee setting; adjustments (1) Inflation adjustment Section 740(c)(2) ( 21 U.S.C. 379j–12(c)(2) ) is amended— (A) in the matter preceding subparagraph (A)— (i) by striking For fiscal year 2015 and inserting (A) For fiscal year 2020 ; and (ii) by inserting multiplying such revenue amounts by before an amount ; (B) by redesignating subparagraphs (A), (B), and (C) as clauses (i), (ii), and (iii), respectively; (C) by striking the flush text at the end; and (D) by adding at the end the following new subparagraph: (B) Compounded basis The adjustment made each fiscal year after fiscal year 2020 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year. . (2) Workload adjustments Paragraph (3) of section 740(c) ( 21 U.S.C. 379j–12(c) ) is amended to read as follows: (3) Workload adjustments (A) In general For fiscal year 2020 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for such fiscal year to reflect changes in the workload of the Secretary for the process for the review of animal drug applications, subject to subparagraphs (B) and (C). With respect to such adjustment— (i) such adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of animal drug applications, supplemental animal drug applications for which data with respect to safety or effectiveness are required, manufacturing supplemental animal drug applications, investigational animal drug study submissions, and investigational animal drug protocol submissions submitted to the Secretary; and (ii) the Secretary shall publish in the Federal Register the fees resulting from such adjustment and the supporting methodologies. (B) Reduction of workload-based increase by amount of certain excess collections For each of fiscal years 2021 through 2023, if application of the workload adjustment under subparagraph (A) increases the fee revenue amounts otherwise established for the fiscal year under subsection (b), as adjusted for inflation under paragraph (2), such fee revenue increase shall be reduced by the amount of any excess collections, as described in subsection (g)(4), for the second preceding fiscal year, up to the amount of such fee revenue increase. (C) Rule of application Under no circumstances shall the workload adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established under subsection (b), as adjusted for inflation under paragraph (2). . (3) Final year adjustment Section 740(c)(4) ( 21 U.S.C. 379j–12(c)(4) ) is amended— (A) by striking 2018 each place it appears and inserting 2023 ; and (B) by striking 2019 and inserting 2024 . (c) Exemptions from fees Section 740(d) ( 21 U.S.C. 379j–12(d) ) is amended— (1) in the subsection heading, by inserting ; exemptions from fees after reduction ; (2) by striking the heading of paragraph (1) and inserting Waiver or reduction ; and (3) by adding at the end the following: (4) Exemptions from fees (A) Certain labeling supplements To add number of approved application Fees under this section shall not apply with respect to any person who— (i) not later than September 30, 2023, submits a supplemental animal drug application relating to a new animal drug application approved under section 512, solely to add the new animal drug application number to the labeling of the drug in the manner specified in section 502(w)(3); and (ii) otherwise would be subject to fees under this section solely on the basis of such supplemental application. (B) Certain animal drug applications Fees under paragraphs (2), (3), and (4) of subsection (a) shall not apply with respect to any person who is the named applicant or sponsor of an animal drug application, supplemental animal drug application, or investigational animal drug submission if such application or submission involves the intentional genomic alteration of an animal that is intended to produce a drug, device, or biological product subject to fees under section 736, 738, 744B, or 744H. . (d) Crediting and availability of fees (1) Authorization of appropriations Section 740(g)(3) ( 21 U.S.C. 379j–12(g)(3) ) is amended— (A) by striking 2014 through 2018 and inserting 2019 through 2023 ; (B) by striking determined and inserting established ; and (C) by striking paragraph (4) and inserting paragraph (5) . (2) Excess collections Section 740(g) ( 21 U.S.C. 379j–12(g) ) is amended by striking paragraph (4) and inserting the following: (4) Excess collections If the sum total of fees collected under this section for a fiscal year exceeds the amount of fees authorized to be appropriated for such year under paragraph (3), the excess collections shall be credited to the appropriations account of the Food and Drug Administration as provided in paragraph (1). (5) Recovery of collection shortfalls (A) In general Subject to subparagraph (B)— (i) for fiscal year 2021, the amount of fees otherwise authorized to be collected under this section shall be increased by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2019 falls below the amount of fees authorized for fiscal year 2019 under paragraph (3); (ii) for fiscal year 2022, the amount of fees otherwise authorized to be collected under this section shall be increased by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2020 falls below the amount of fees authorized for fiscal year 2020 under paragraph (3); and (iii) for fiscal year 2023, the amount of fees otherwise authorized to be collected under this section shall be increased by the cumulative amount, if any, by which the amount collected under this section and appropriated for fiscal years 2021 and 2022 (including estimated collections for fiscal year 2022) falls below the cumulative amount of fees authorized for such fiscal years under paragraph (3). (B) Reduction of shortfall-based fee increase by prior year excess collections (i) In general Subject to clause (ii), the Secretary shall, in such manner as the Secretary determines appropriate, reduce any fee increase otherwise applicable for a fiscal year under subparagraph (A) by the amount of any excess collections under this section for preceding fiscal years (after fiscal year 2018). (ii) Workload-based fee accounting In applying clause (i), the Secretary shall account for the reduction of workload-based fee revenue increases by excess collections under subsection (c)(3)(B), in such manner as needed to provide that no portion of any excess collections described in clause (i) is applied for purposes of reducing fee increases under both such subsection (c)(3)(B) and this paragraph. (C) Rule of application Under no circumstances shall adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established in subsection (b), as adjusted or otherwise affected under subsection (c). . 104. Reauthorization; reporting requirements Section 740A ( 21 U.S.C. 379j–13 ) is amended— (1) in subsection (a), by striking 2013 and inserting 2018 ; (2) by striking 2014 each place it appears in subsections (a) and (b) and inserting 2019 ; and (3) in subsection (d), by striking 2018 each place it appears and inserting 2023 . 105. Savings clause Notwithstanding the amendments made by this title, part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–11 et seq.), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after October 1, 2013, but before October 1, 2018, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019. 106. Effective date The amendments made by this title shall take effect on October 1, 2018, or the date of the enactment of this Act, whichever is later, except that fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as amended by this title, shall be assessed for animal drug applications and supplemental animal drug applications received on or after October 1, 2018, regardless of the date of the enactment of this Act. 107. Sunset dates (a) Authorization Section 740 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–12 ) shall cease to be effective October 1, 2023. (b) Reporting requirements Section 740A of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–13 ) shall cease to be effective January 31, 2024. (c) Previous sunset provision Effective October 1, 2018, subsections (a) and (b) of section 107 of the Animal Drug User Fee Amendments of 2013 ( Public Law 113–14 ) are repealed. II Fees Relating to Generic Animal Drugs 201. Short title; finding (a) Short title This title may be cited as the Animal Generic Drug User Fee Amendments of 2018 . (b) Finding Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the generic new animal drug development process and the review of abbreviated applications for generic new animal drugs, supplemental abbreviated applications for generic new animal drugs, and investigational submissions for generic new animal drugs as set forth in the goals identified for purposes of part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor and Pensions of the Senate as set forth in the Congressional Record. 202. Authority to assess and use generic new animal drug fees (a) Fee revenue amounts Subsection (b) of section 741 ( 21 U.S.C. 379j–21 ) is amended to read as follows: (b) Fee revenue amounts (1) In general Subject to subsections (c), (d), (f), and (g), for each of fiscal years 2019 through 2023, the fees required under subsection (a) shall be established to generate a total revenue amount of $18,336,340. (2) Types of fees Of the total revenue amount established for a fiscal year under paragraph (1)— (A) 25 percent shall be derived from fees under subsection (a)(1) (relating to abbreviated applications for a generic new animal drug); (B) 37.5 percent shall be derived from fees under subsection (a)(2) (relating to generic new animal drug products); and (C) 37.5 percent shall be derived from fees under subsection (a)(3) (relating to generic new animal drug sponsors). . (b) Annual fee setting; adjustments (1) Inflation adjustment Section 741(c) ( 21 U.S.C. 379j–21(c) ) is amended— (A) by redesignating paragraphs (2) through (4) as paragraphs (3) through (5), respectively; and (B) by inserting after paragraph (1) the following: (2) Inflation adjustment (A) In general For fiscal year 2020 and subsequent fiscal years, the revenue amounts established under subsection (b) shall be adjusted by the Secretary by notice, published in the Federal Register, for a fiscal year, by multiplying such revenue amounts by an amount equal to the sum of— (i) one; (ii) the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 of the preceding 4 fiscal years for which data are available, multiplied by the average proportion of personnel compensation and benefits costs to total Food and Drug Administration costs for the first 3 of the preceding 4 fiscal years for which data are available; and (iii) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; not seasonally adjusted; all items less food and energy; annual index) for the first 3 of the preceding 4 years for which data are available multiplied by the average proportion of all costs other than personnel compensation and benefits costs to total Food and Drug Administration costs for the first 3 of the preceding 4 fiscal years for which data are available. (B) Compounded basis The adjustment made each fiscal year after fiscal year 2020 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year. . (2) Workload adjustments Paragraph (3) of section 741(c) ( 21 U.S.C. 379j–21(c) ), as redesignated, is amended to read as follows: (3) Workload adjustments (A) In general For fiscal year 2020 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for each such fiscal year to reflect changes in the workload of the Secretary for the process for the review of abbreviated applications for generic new animal drugs, subject to subparagraphs (B) and (C). With respect to such adjustment— (i) this adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of abbreviated applications for generic new animal drugs, manufacturing supplemental abbreviated applications for generic new animal drugs, investigational generic new animal drug study submissions, and investigational generic new animal drug protocol submissions submitted to the Secretary; and (ii) the Secretary shall publish in the Federal Register the fees resulting from this adjustment and the supporting methodologies. (B) Reduction of workload-based increase by amount of certain excess collections For each of fiscal years 2021 through 2023, if application of the workload adjustment under subparagraph (A) increases the fee revenue amounts otherwise established for the fiscal year under subsection (b), as adjusted for inflation under paragraph (2), such fee revenue increase shall be reduced by the amount of any excess collections, as described in subsection (g)(4), for the second preceding fiscal year, up to the amount of such fee revenue increase. (C) Rule of application Under no circumstances shall workload adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established under subsection (b), as adjusted for inflation under paragraph (2). . (3) Final year adjustment Paragraph (4) of section 741(c) ( 21 U.S.C. 379j–21(c) ), as redesignated, is amended by— (A) striking 2018 each place it appears and inserting 2023 ; and (B) striking 2019 and inserting 2024 . (c) Fee waiver or reduction; exemption from fees Subsection (d) of section 741 ( 21 U.S.C. 379j–21 ) is amended to read as follows: (d) Fee waiver or reduction; exemption from fees (1) Fee waiver or reduction The Secretary shall grant a waiver from or a reduction of one or more fees assessed under subsection (a) where the Secretary finds that the generic new animal drug is intended solely to provide for a minor use or minor species indication. (2) Exemption from fees Fees under this section shall not apply with respect to any person who— (A) not later than September 30, 2023, submits a supplemental abbreviated application for a generic new animal drug approved under section 512, solely to add the application number to the labeling of the drug in the manner specified in section 502(w)(3); and (B) otherwise would be subject to fees under this section solely on the basis of such supplemental abbreviated application. . (d) Crediting and availability of fees Section 741(g) ( 21 U.S.C. 379j–21 ) is amended by striking paragraph (3) and inserting the following paragraphs: (3) Authorization of appropriations For each of the fiscal years 2019 through 2023, there is authorized to be appropriated for fees under this section an amount equal to the total revenue amount established under subsection (b) for the fiscal year, as adjusted or otherwise affected under subsection (c). (4) Excess collections If the sum total of fees collected under this section for a fiscal year exceeds the amount of fees authorized to be appropriated for such year under paragraph (3), the excess collections shall be credited to the appropriations account of the Food and Drug Administration as provided in paragraph (1). . 203. Reauthorization; reporting requirements Section 742 ( 21 U.S.C. 379j–22 ) is amended— (1) in subsection (a), by striking 2013 and inserting 2018 ; (2) in subsection (b), by striking Committee on Health, Education, Labor, and Pensions and inserting the Committee on Health, Education, Labor and Pensions ; (3) by striking 2014 each place it appears in subsections (a) and (b) and inserting 2019 ; and (4) in subsection (d), by striking 2018 each place it appears and inserting 2023 . 204. Savings clause Notwithstanding the amendments made by this title, part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 et seq.), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug (as defined in such part as of such day) that on or after October 1, 2013, but before October 1, 2018, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019. 205. Effective date The amendments made by this title shall take effect on October 1, 2018, or the date of the enactment of this Act, whichever is later, except that fees under part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as amended by this title, shall be assessed for abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug received on or after October 1, 2018, regardless of the date of enactment of this Act. 206. Sunset dates (a) Authorization Section 741 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 ) shall cease to be effective October 1, 2023. (b) Reporting requirements Section 742 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–22 ) shall cease to be effective January 31, 2024. (c) Previous sunset provision Effective October 1, 2018, subsections (a) and (b) of section 206 of the Animal Generic Drug User Fee Amendments of 2013 ( Public Law 113–14 ) are repealed. III Miscellaneous Provisions 301. Electronic submissions (a) New animal drug applications and abbreviated applications for a generic new animal drug Section 512(b) ( 21 U.S.C. 360b(b) ) is amended by adding at the end the following: (4) Beginning on October 1, 2018, all applications or submissions pursuant to this subsection shall be submitted by electronic means in such format as the Secretary may require. . (b) Conditional approval of new animal drugs for minor use and minor species Section 571(a) ( 21 U.S.C. 360ccc(a) ) is amended by adding at the end the following: (4) Beginning on October 1, 2018, all applications or submissions pursuant to this subsection shall be submitted by electronic means in such format as the Secretary may require. . 302. Index of legally marketed unapproved new animal drugs for minor species Effective on October 1, 2018, section 572(h) ( 21 U.S.C. 360ccc–1(h) ) is amended— (1) by amending paragraph (1) to read as follows: (1) LEGAL STATUS—In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the Food and Drug Administration. THIS PRODUCT IS INDEXED—MIF # (followed by the applicable minor species index file number and a period) Extra-label use is prohibited. ; ; and (2) in paragraph (2), by striking other animals and inserting food-producing animals . 303. Misbranded drugs and devices (a) In general Section 502(w) ( 21 U.S.C. 352(w) ) is amended— (1) in subparagraph (1), by striking ; or and inserting ; ; (2) in subparagraph (2), by striking the period and inserting ; or ; and (3) by adding at the end the following: (3) for which an application has been approved under section 512 and the labeling of such drug does not include the application number in the format: Approved by FDA under (A)NADA # xxx–xxx , except that this subparagraph shall not apply to representative labeling required under section 514.1(b)(3)(v)(b) of title 21, Code of Federal Regulations (or any successor regulation) for animal feed bearing or containing a new animal drug. . (b) Applicability Section 502(w)(3) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), shall apply beginning on September 30, 2023. 304. Conditional approval of new animal drugs (a) In general Section 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ccc ) is amended— (1) in the section heading, by striking species and inserting species and certain new animal drugs ; (2) in subsection (a)— (A) by amending paragraph (1) to read as follows: (1) (A) Except as provided in paragraph (3), any person may file with the Secretary an application for conditional approval of— (i) a new animal drug intended for a minor use or a minor species; or (ii) a new animal drug not intended for a minor use or minor species— (I) that is intended to treat a serious or life-threatening disease or condition or addresses an unmet animal or human health need; and (II) for which the Secretary determines that a demonstration of effectiveness would require a complex or particularly difficult study or studies. (B) The Secretary shall, not later than September 30, 2019, issue guidance or regulations further clarifying the criteria specified in subparagraph (A)(ii). (C) An application under this paragraph shall comply in all respects with the provisions of section 512 except for subsections (a)(4), (b)(2), (c)(1), (c)(2), (c)(3), (d)(1), (e), (h), and (n) of such section unless otherwise stated in this section, and any additional provisions of this section. (D) New animal drugs for which conditional approval is sought under this section are subject to the same safety standards that would be applied to new animal drugs under section 512(d) (including, for antimicrobial new animal drugs, with respect to antimicrobial resistance). ; and (B) in paragraph (3)— (i) in subparagraph (B), by striking , or and inserting ; or ; (ii) by redesignating subparagraphs (A), (B), and (C) as clauses (i), (ii), and (iii), respectively; (iii) by striking A person may not file and inserting (A) A person may not file ; and (iv) by adding at the end the following new subparagraph: (B) A person may not file an application under paragraph (1)(A)(ii) if the application seeks conditional approval of a new animal drug that contains an antimicrobial active ingredient. ; (3) in subsection (f)— (A) in paragraph (1), in the matter preceding subparagraph (A), by inserting for the conditionally approved use after shall ; and (B) in paragraph (2)— (i) by striking An intended use and inserting The Secretary shall, through regulation or guidance, determine under what conditions an intended use ; and (ii) by striking shall not and inserting may ; and (4) by adding at the end the following new subsection: (k) Sunset (1) The Secretary’s authority to grant conditional approval of new animal drugs not intended for a minor use or minor species pursuant to subsection (a)(1)(A)(ii) terminates on October 1, 2028. (2) The Secretary— (A) may not accept any new applications for such conditional approval pursuant to subsection (a)(1)(A)(ii) on or after such date; and (B) may continue all activities under this section with respect to drugs that were conditionally approved pursuant to (a)(1)(A)(ii) prior to such date. (3) The Secretary may, until October 1, 2032, accept applications for approval under 512 of drugs conditionally approved pursuant to (a)(1)(A)(ii). . (b) Exception from fees in case of certain previously submitted applications for conditional approval Section 740(a)(1)(C) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–12(a)(1)(C) ) is amended— (1) in the caption by striking Exception and inserting Exceptions ; (2) by striking If an animal drug and inserting the following: (i) If an animal drug ; and (3) by inserting after clause (i), as so designated, the following new clause: (ii) Beginning with fiscal year 2019, in the case of an animal drug application submitted by a person under section 512(b)(1), where such person (or their licensor, assignor, or predecessor-in-interest) previously submitted an application for conditional approval under section 571 for the same product and paid the applicable fee under subparagraph (A), the application under section 512(b)(1) shall not be subject to a fee under subparagraph (A) if submitted within the timeframe specified in section 571(h). . (c) Report on incorporating veterinary oversight Not later than September 30, 2019, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall submit a report to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor and Pensions of the Senate identifying how the Food and Drug Administration will incorporate veterinary oversight for all approved medically important antimicrobial drugs administered to animals that are not yet subject to veterinary oversight. Such report shall address requirements related to revisions of labeling to reflect that medically important antimicrobial drugs administered to animals shall be subject to veterinary oversight. (d) GAO study of conditional approval programs (1) Study The Comptroller General of the United States (referred to in this section as the Comptroller General ) shall conduct a study on the effectiveness and overall impact of the conditional approval pathway under section 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ccc ). (2) Issuance of report Not later than January 1, 2026, the Comptroller General shall submit to the Committee on Health, Education, Labor and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing the results of the study under paragraph (1). (3) Contents of reports The report submitted under paragraph (2) shall address— (A) for each drug for which a conditional approval has been awarded since October 1, 2018— (i) whether the drug was granted conditional approval pursuant to clause (i) or (ii) of section 571(a)(1)(A) of the Federal Food, Drug, and Cosmetic Act, as amended by subsection (a); (ii) whether the drug was dual labeled during its conditional approval; (iii) the indications for which the drug was granted conditional approval under section 571 of such Act ( 21 U.S.C. 360ccc ) and whether the drug was approved or not approved under section 512 of such Act ( 21 U.S.C. 360b ); (iv) the number of years the drug was so conditionally approved and a description of the complexity of the investigation to demonstrate the drug’s effectiveness; (v) whether, and to what extent, the conditional approval pathway under such section 571 ( 21 U.S.C. 360ccc ) impacted the sponsor’s decision to develop the drug or seek approval of the drug under section 512 of such Act ( 21 U.S.C. 360b ); (vi) whether, and to what extent, conditional approval pursuant to clause (ii) of section 571(a)(1)(A) of such Act ( 21 U.S.C. 360b(a)(1)(A) ) addressed a serious or life-threatening condition; and (vii) whether, and to what extent, conditional approval pursuant to clause (ii) of section 571(a)(1)(A) of such Act ( 21 U.S.C. 360b(a)(1)(A) ) addressed an unmet animal or human health need, and whether before such conditional approval there were available therapies for the disease or condition involved; (B) an analysis of the conditional approval program under section 571 of such Act ( 21 U.S.C. 360ccc ), including— (i) the resources used by the Food and Drug Administration in reviewing applications for conditional approval of drugs pursuant to such program and renewal of such conditional approval, including the effects of the program on the Food and Drug Administration’s review of animal drugs for which conditional approval is not used; (ii) whether any improvements to the program under section 512 of such Act ( 21 U.S.C. 360b ) are necessary to incentivize the development of animal drugs that would likely not otherwise be developed, or developed in as timely a manner, to address— (I) serious or life-threatening conditions; and (II) an unmet animal or human health need; and (iii) whether the conditional approval pathway has resulted in a greater number of animal drugs approved under section 512 of such Act ( 21 U.S.C. 360b ) for serious or life-threatening conditions or unmet animal or human health needs than would have otherwise come to market under the practices and commitments of the Center for Veterinary Medicine of the Food and Drug Administration as such practices and commitments existed as of the day before the date of enactment of this Act; and (C) how the Center for Veterinary Medicine of the Food and Drug Administration has utilized complex adaptive or other novel investigation designs, data from foreign countries, real-world evidence (including ongoing surveillance activities, observational studies, and registry data), biomarkers, or surrogate endpoints— (i) to support the approval of products under section 512 of such Act ( 21 U.S.C. 360b ), including how many such products have been approved since October 1, 2018; and (ii) to support the approval of products under section 512 of such Act ( 21 U.S.C. 360b ) that received conditional approval under section 571 of such Act ( 21 U.S.C. 360ccc ), including how many such products have been approved since October 1, 2018. 305. Guidance addressing investigation designs (a) In general For purposes of assisting sponsors in incorporating complex adaptive and other novel investigation designs, data from foreign countries, real world evidence (including ongoing surveillance activities, observational studies, and registry data), biomarkers, and surrogate endpoints (referred to in this section as elements of investigations ) into proposed clinical investigation protocols and applications for new animal drugs under sections 512 and 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360b ; 360ccc), the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall issue guidance addressing the use of such elements of investigations in the development and regulatory review of such new animal drugs. (b) Contents The guidance under subsection (a) shall address how the Secretary will evaluate the elements of investigations proposed or submitted pursuant to section 512(b)(1)(A) of the Federal Food, Drug, and Cosmetic Act or to meet the commitment under section 571(a)(2)(F) of such Act, and how sponsors of such applications may obtain feedback from the Secretary on technical issues related to such investigations prior to the submission of an application to the Secretary. (c) Meeting Prior to issuing the guidance under subsection (a), the Secretary shall consult with stakeholders, including representatives of regulated industry, consumer groups, academia, veterinarians, and food producers, through a public meeting to be held not later than 1 year after the date of enactment of this Act. (d) Timing The Secretary shall issue a draft guidance under subsection (a) not later than 1 year after the date of the public meeting under subsection (c), and shall finalize such guidance not later than 1 year after the date on which the public comment period on such draft guidance ends. 306. Food additives intended for use in animal food (a) Food additive petitions for animal food Section 409 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 348 ) is amended by adding at the end the following: (k) Food additives intended for use in animal food (1) In taking action on a petition under subsection (c) for, or for recognition of, a food additive intended for use in animal food, the Secretary shall review reports of investigations conducted in foreign countries, provided by the petitioner. (2) Not later than 12 months after the date of enactment of the Animal Drug and Animal Generic Drug Use Fee Amendments of 2018, the Secretary shall post on the internet website of the Food and Drug Administration— (A) the number of petitions for food additives intended for use in animal food filed under subsection (b) that are pending; (B) how long each such petition submitted under subsection (b) has been pending, including such petitions the Secretary has extended under subsection (c)(2); and (C) the number of study protocols that have been pending review for over 50 days, and the number that have received an extension. (3) In the case of a food additive petition intended for use in animal food, the Secretary shall provide information to the petitioner on the required contents of such petition. If the Secretary requires additional studies beyond what the petitioner proposed, the Secretary shall provide the scientific rationale for such requirement. . (b) Ensuring the safety of pet food Section 1002(a) of the Food and Drug Administration Amendments Act of 2007 ( 21 U.S.C. 2102(a) ) is amended— (1) by striking paragraph (1); and (2) by redesignating paragraphs (2) and (3) as paragraphs (1) and (2), respectively. (c) Guidance on pre-Petition consultation process for animal food additives (1) In general Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this subsection as the Secretary ) shall publish draft guidance relating to the voluntary pre-petition consultation process for food additives intended for use in animal food. (2) Contents The guidance under paragraph (1) shall include— (A) the recommended format to submit to the Food and Drug Administration existing data, including any applicable foreign data, for assessment prior to submission of a food additive petition for animal food under section 409(b) of the Federal Food, Drug, and Cosmetic Act; (B) the manner and the number of days by which the Food and Drug Administration intends to review and respond to such existing data, including with respect to providing a scientific rationale for any additional data request; (C) circumstances under which the submission of study protocols is recommended prior to submission of a food additive petition under such section 409(b); (D) the manner in which the Secretary intends to inform the person submitting a study protocol for a food additive if the review of such study protocol will take longer than 50 days; and (E) best practices for communication between the Food and Drug Administration and industry on the development of pre-petition submissions of study protocols and existing data for food additives. (3) Final guidance The guidance under paragraph (1) shall be finalized, withdrawn, or reissued not later than 1 year after the close of the comment period on the draft guidance.

Speaker of the House of Representatives. Vice President of the United States and President of the Senate.

tv_txt: I 115th CONGRESS 2d Session H. R. 5554 IN THE HOUSE OF REPRESENTATIVES April 18, 2018 Mr. Mullin (for himself, Mr. Schrader , Mr. Walden , Mr. Pallone , Mr. Burgess , and Mr. Gene Green of Texas ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.

1. Short title This Act may be cited as the Animal Drug and Animal Generic Drug User Fee Amendments of 2018 . 2. Table of contents; references in Act (a) Table of contents The table of contents for this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents; references in Act. Title I—Fees Relating to Animal Drugs Sec. 101. Short title; finding. Sec. 102. Definitions. Sec. 103. Authority to assess and use animal drug fees. Sec. 104. Reauthorization; reporting requirements. Sec. 105. Savings clause. Sec. 106. Effective date. Sec. 107. Sunset dates. Title II—Fees Relating to Generic Animal Drugs Sec. 201. Short title; finding. Sec. 202. Authority to assess and use generic new animal drug fees. Sec. 203. Reauthorization; reporting requirements. Sec. 204. Savings clause. Sec. 205. Effective date. Sec. 206. Sunset dates. Title III—Miscellaneous Provisions Sec. 301. Electronic submissions. Sec. 302. Index of legally marketed unapproved new animal drugs for minor species. Sec. 303. Misbranded drugs and devices. (b) References in Act Except as otherwise specified, amendments made by this Act to a section or other provision of law are amendments to such section or other provision of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq.). I Fees Relating to Animal Drugs 101. Short title; finding (a) Short title This title may be cited as the Animal Drug User Fee Amendments of 2018 . (b) Finding Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the animal drug development process and the review of new and supplemental animal drug applications and investigational animal drug submissions as set forth in the goals identified for purposes of part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate as set forth in the Congressional Record. 102. Definitions Section 739 ( 21 U.S.C. 379j–11 ) is amended— (1) by amending paragraph (1) to read as follows: (1) (A) The term animal drug application means— (i) an application for approval of any new animal drug submitted under section 512(b)(1); or (ii) an application for conditional approval of a new animal drug submitted under section 571. (B) Such term does not include either a new animal drug application submitted under section 512(b)(2) or a supplemental animal drug application. ; and (2) in paragraph (8), by adding at the end the following: (I) The activities necessary for implementation of the United States and European Union Good Manufacturing Practice Mutual Inspection Agreement with respect to animal drug products subject to review, including implementation activities prior to and following product approval. . 103. Authority to assess and use animal drug fees (a) Fee revenue amounts Section 740(b) ( 21 U.S.C. 379j–12(b) ) is amended— (1) in paragraph (1)— (A) in subparagraph (A)— (i) by striking 2014 and inserting 2019 ; and (ii) by striking $23,600,000 and inserting $30,331,240 ; and (B) in subparagraph (B)— (i) by striking 2015 through 2018 and inserting 2020 through 2023 ; and (ii) by striking $21,600,000 and inserting $29,931,240 ; and (2) in paragraph (2), in the matter preceding subparagraph (A), by striking determined and inserting established . (b) Annual fee setting; adjustments (1) Inflation adjustment Section 740(c)(2) ( 21 U.S.C. 379j–12(c)(2) ) is amended— (A) in the matter preceding subparagraph (A)— (i) by striking For fiscal year 2015 and inserting (A) For fiscal year 2020 ; and (ii) by inserting multiplying such revenue amounts by before an amount ; (B) by redesignating subparagraphs (A), (B), and (C) as clauses (i), (ii), and (iii), respectively; (C) by striking the flush text at the end; and (D) by adding at the end the following new subparagraph: (B) Compounded basis The adjustment made each fiscal year after fiscal year 2020 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year. . (2) Workload adjustments Paragraph (3) of section 740(c) ( 21 U.S.C. 379j–12(c) ) is amended to read as follows: (3) Workload adjustments (A) In general For fiscal year 2020 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for such fiscal year to reflect changes in the workload of the Secretary for the process for the review of animal drug applications, subject to subparagraphs (B) and (C). With respect to such adjustment— (i) such adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of animal drug applications, supplemental animal drug applications for which data with respect to safety or effectiveness are required, manufacturing supplemental animal drug applications, investigational animal drug study submissions, and investigational animal drug protocol submissions submitted to the Secretary; and (ii) the Secretary shall publish in the Federal Register the fees resulting from such adjustment and the supporting methodologies. (B) Reduction of workload-based increase by amount of certain excess collections For each of fiscal years 2021 through 2023, if application of the workload adjustment under subparagraph (A) increases the fee revenue amounts otherwise established for the fiscal year under subsection (b), as adjusted for inflation under paragraph (2), such fee revenue increase shall be reduced by the amount of any excess collections, as described in subsection (g)(4), for the second preceding fiscal year, up to the amount of such fee revenue increase. (C) Rule of application Under no circumstances shall the workload adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established under subsection (b), as adjusted for inflation under paragraph (2). . (3) Final year adjustment Section 740(c)(4) ( 21 U.S.C. 379j–12(c)(4) ) is amended— (A) by striking 2018 each place it appears and inserting 2023 ; and (B) by striking 2019 and inserting 2024 . (c) Exemptions from fees Section 740(d) ( 21 U.S.C. 379j–12(d) ) is amended— (1) in the subsection heading, by inserting ; exemptions from fees after reduction ; (2) by striking the heading of paragraph (1) and inserting Waiver or reduction ; and (3) by adding at the end the following: (4) Exemptions from fees (A) Certain labeling supplements To add number of approved application Fees under this section shall not apply with respect to any person who— (i) not later than September 30, 2023, submits a supplemental animal drug application relating to a new animal drug application approved under section 512, solely to add the new animal drug application number to the labeling of the drug in the manner specified in section 502(w)(3); and (ii) otherwise would be subject to fees under this section solely on the basis of such supplemental application. (B) Certain animal drug applications Fees under paragraphs (2), (3), and (4) of subsection (a) shall not apply with respect to any person who is the named applicant or sponsor of an animal drug application, supplemental animal drug application, or investigational animal drug submission if such application or submission involves the intentional genomic alteration of an animal that is intended to produce a drug, device, or biological product subject to fees under section 736, 738, 744B, or 744H. . (d) Crediting and availability of fees (1) Authorization of appropriations Section 740(g)(3) ( 21 U.S.C. 379j–12(g)(3) ) is amended— (A) by striking 2014 through 2018 and inserting 2019 through 2023 ; (B) by striking determined and inserting established ; and (C) by striking paragraph (4) and inserting paragraph (5) . (2) Excess collections Section 740(g) ( 21 U.S.C. 379j–12(g) ) is amended by striking paragraph (4) and inserting the following: (4) Excess collections If the sum total of fees collected under this section for a fiscal year exceeds the amount of fees authorized to be appropriated for such year under paragraph (3), the excess collections shall be credited to the appropriations account of the Food and Drug Administration as described in paragraph (1). (5) Recovery of collection shortfalls (A) In general Subject to subparagraph (B)— (i) for fiscal year 2021, the amount of fees otherwise authorized to be collected under this section shall be increased by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2019 falls below the amount of fees authorized for fiscal year 2019 under paragraph (3); (ii) for fiscal year 2022, the amount of fees otherwise authorized to be collected under this section shall be increased by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2020 falls below the amount of fees authorized for fiscal year 2020 under paragraph (3); and (iii) for fiscal year 2023, the amount of fees otherwise authorized to be collected under this section shall be increased by the cumulative amount, if any, by which the amount collected under this section and appropriated for fiscal years 2021 and 2022 (including estimated collections for fiscal year 2022) falls below the cumulative amount of fees authorized for such fiscal years under paragraph (3). (B) Reduction of shortfall-based fee increase by prior year excess collections (i) In general Subject to clause (ii), the Secretary shall, in such manner as the Secretary determines appropriate, reduce any fee increase otherwise applicable for a fiscal year under subparagraph (A) by the amount of any excess collections under this section for preceding fiscal years (after fiscal year 2018). (ii) Workload-based fee accounting In applying clause (i), the Secretary shall account for the reduction of workload-based fee revenue increases by excess collections under subsection (c)(3)(B), in such manner as needed to provide that no portion of any excess collections described in clause (i) is applied for purposes of reducing fee increases under both such subsection (c)(3)(B) and this paragraph. (C) Rule of application Under no circumstances shall adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established in subsection (b), as adjusted or otherwise affected under subsection (c). . 104. Reauthorization; reporting requirements Section 740A ( 21 U.S.C. 379j–13 ) is amended— (1) in subsection (a), by striking 2013 and inserting 2018 ; (2) by striking 2014 each place it appears in subsections (a) and (b) and inserting 2019 ; and (3) in subsection (d), by striking 2018 each place it appears and inserting 2023 . 105. Savings clause Notwithstanding the amendments made by this title, part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–11 et seq.), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after October 1, 2013, but before October 1, 2018, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019. 106. Effective date The amendments made by this title shall take effect on October 1, 2018, or the date of the enactment of this Act, whichever is later, except that fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as amended by this title, shall be assessed for animal drug applications and supplemental animal drug applications received on or after October 1, 2018, regardless of the date of the enactment of this Act. 107. Sunset dates (a) Authorization Section 740 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–12 ) shall cease to be effective October 1, 2023. (b) Reporting requirements Section 740A of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–13 ) shall cease to be effective January 31, 2024. (c) Previous sunset provision Effective October 1, 2018, subsections (a) and (b) of section 107 of the Animal Drug User Fee Amendments of 2013 ( Public Law 113–14 ) are repealed. II Fees Relating to Generic Animal Drugs 201. Short title; finding (a) Short title This title may be cited as the Animal Generic Drug User Fee Amendments of 2018 . (b) Finding Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the generic new animal drug development process and the review of abbreviated applications for generic new animal drugs, supplemental abbreviated applications for generic new animal drugs, and investigational submissions for generic new animal drugs as set forth in the goals identified for purposes of part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor and Pensions of the Senate as set forth in the Congressional Record. 202. Authority to assess and use generic new animal drug fees (a) Fee revenue amounts Subsection (b) of section 741 ( 21 U.S.C. 379j–21 ) is amended to read as follows: (b) Fee revenue amounts (1) In general Subject to subsections (c), (d), (f), and (g), for each of fiscal years 2019 through 2023, the fees required under subsection (a) shall be established to generate a total revenue amount of $18,336,340. (2) Types of fees Of the total revenue amount established for a fiscal year under paragraph (1)— (A) 25 percent shall be derived from fees under subsection (a)(1) (relating to abbreviated applications for a generic new animal drug); (B) 37.5 percent shall be derived from fees under subsection (a)(2) (relating to generic new animal drug products); and (C) 37.5 percent shall be derived from fees under subsection (a)(3) (relating to generic new animal drug sponsors). . (b) Annual fee setting; adjustments (1) Inflation adjustment Section 741(c) ( 21 U.S.C. 379j–21(c) ) is amended— (A) by redesignating paragraphs (2) through (4) as paragraphs (3) through (5), respectively; and (B) by inserting after paragraph (1) the following: (2) Inflation adjustment (A) In general For fiscal year 2020 and subsequent fiscal years, the revenue amounts established under subsection (b) shall be adjusted by the Secretary by notice, published in the Federal Register, for a fiscal year, by multiplying such revenue amounts by an amount equal to the sum of— (i) one; (ii) the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first three of the preceding 4 fiscal years for which data are available, multiplied by the average proportion of personnel compensation and benefits costs to total Food and Drug Administration costs for the first three of the preceding 4 fiscal years for which data are available; and (iii) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; not seasonally adjusted; all items less food and energy; annual index) for the first three of the preceding 4 years for which data are available multiplied by the average proportion of all costs other than personnel compensation and benefits costs to total Food and Drug Administration costs for the first three of the preceding 4 fiscal years for which data are available. (B) Compounded basis The adjustment made each fiscal year after fiscal year 2020 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year. . (2) Workload adjustments Paragraph (3) of section 741(c) ( 21 U.S.C. 379j–21(c) ), as redesignated, is amended to read as follows: (3) Workload adjustments (A) In general For fiscal year 2020 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for each such fiscal year to reflect changes in the workload of the Secretary for the process for the review of abbreviated applications for generic new animal drugs, subject to subparagraphs (B) and (C). With respect to such adjustment— (i) this adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of abbreviated applications for generic new animal drugs, manufacturing supplemental abbreviated applications for generic new animal drugs, investigational generic new animal drug study submissions, and investigational generic new animal drug protocol submissions submitted to the Secretary; and (ii) the Secretary shall publish in the Federal Register the fees resulting from this adjustment and the supporting methodologies. (B) Reduction of workload-based increase by amount of certain excess collections For each of fiscal years 2021 through 2023, if application of the workload adjustment under subparagraph (A) increases the fee revenue amounts otherwise established for the fiscal year under subsection (b), as adjusted for inflation under paragraph (2), such fee revenue increase shall be reduced by the amount of any excess collections, as described in subsection (g)(4), for the second preceding fiscal year, up to the amount of such fee revenue increase. (C) Rule of application Under no circumstances shall workload adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established under subsection (b), as adjusted for inflation under paragraph (2). . (3) Final year adjustment Paragraph (4) of section 741(c) ( 21 U.S.C. 379j–21(c) ), as redesignated, is amended by— (A) striking 2018 each place it appears and inserting 2023 ; and (B) striking 2019 and inserting 2024 . (c) Fee waiver or reduction; exemption from fees Subsection (d) of section 741 ( 21 U.S.C. 379j–21 ) is amended to read as follows: (d) Fee waiver or reduction; exemption from fees (1) Fee waiver or reduction The Secretary shall grant a waiver from or a reduction of one or more fees assessed under subsection (a) where the Secretary finds that the generic new animal drug is intended solely to provide for a minor use or minor species indication. (2) Exemption from fees Fees under this section shall not apply with respect to any person who— (A) not later than September 30, 2023, submits a supplemental abbreviated application for a generic new animal drug approved under section 512, solely to add the application number to the labeling of the drug in the manner specified in section 502(w)(3); and (B) otherwise would be subject to fees under this section solely on the basis of such supplemental abbreviated application. . (d) Crediting and availability of fees Section 741(g) ( 21 U.S.C. 379j–21 ) is amended by striking paragraph (3) and inserting the following paragraphs: (3) Authorization of appropriations For each of the fiscal years 2019 through 2023, there is authorized to be appropriated for fees under this section an amount equal to the total revenue amount established under subsection (b) for the fiscal year, as adjusted or otherwise affected under subsection (c). (4) Excess collections If the sum total of fees collected under this section for a fiscal year exceeds the amount of fees authorized to be appropriated for such year under paragraph (3), the excess collections shall be credited to the appropriations account of the Food and Drug Administration as described in paragraph (1). . 203. Reauthorization; reporting requirements Section 742 ( 21 U.S.C. 379j–22 ) is amended— (1) in subsection (a), by striking 2013 and inserting 2018 ; (2) in subsection (b), by striking Committee on Health, Education, Labor, and Pensions and inserting the Committee on Health, Education, Labor and Pensions ; (3) by striking 2014 each place it appears in subsections (a) and (b) and inserting 2019 ; and (4) in subsection (d), by striking 2018 each place it appears and inserting 2023 . 204. Savings clause Notwithstanding the amendments made by this title, part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 et seq.), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug (as defined in such part as of such day) that on or after October 1, 2013, but before October 1, 2018, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019. 205. Effective date The amendments made by this title shall take effect on October 1, 2018, or the date of the enactment of this Act, whichever is later, except that fees under part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as amended by this title, shall be assessed for abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug received on or after October 1, 2018, regardless of the date of enactment of this Act. 206. Sunset dates (a) Authorization Section 741 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 ) shall cease to be effective October 1, 2023. (b) Reporting requirements Section 742 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–22 ) shall cease to be effective January 31, 2024. (c) Previous sunset provision Effective October 1, 2018, subsections (a) and (b) of section 206 of the Animal Generic Drug User Fee Amendments of 2013 ( Public Law 113–14 ) are repealed. III Miscellaneous Provisions 301. Electronic submissions (a) New animal drug applications and abbreviated applications for a generic new animal drug Section 512(b) ( 21 U.S.C. 360b(b) ) is amended by adding at the end the following: (4) Beginning on October 1, 2018, all applications or submissions pursuant to this subsection shall be submitted by electronic means in such format as the Secretary may require. . (b) Conditional approval of new animal drugs for minor use and minor species Section 571(a) ( 21 U.S.C. 360ccc(a) ) is amended by adding at the end the following: (4) Beginning on October 1, 2018, all applications or submissions pursuant to this subsection shall be submitted by electronic means in such format as the Secretary may require. . 302. Index of legally marketed unapproved new animal drugs for minor species Effective on October 1, 2018, section 572(h) ( 21 U.S.C. 360ccc–1(h) ) is amended— (1) by amending paragraph (1) to read as follows: (1) LEGAL STATUS—In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the Food and Drug Administration. THIS PRODUCT IS INDEXED—MIF. (followed by the applicable minor species index file number and a period) Extra-label use is prohibited. ; ; and (2) in paragraph (2), by striking other animals and inserting food-producing animals . 303. Misbranded drugs and devices (a) In general Section 502(w) ( 21 U.S.C. 352(w) ) is amended— (1) in subparagraph (1), by striking ; or and inserting ; ; (2) in subparagraph (2), by striking the period and inserting ; or ; and (3) by adding at the end the following: (3) for which an application has been approved under section 512 and the labeling of such drug does not include the application number in the format: Approved by FDA under (A)NADA # xxx–xxx , except that this subparagraph shall not apply to representative labeling required under section 514.1(b)(3)(v)(b) of title 21, Code of Federal Regulations (or any successor regulation) for animal feed bearing or containing a new animal drug. . (b) Applicability Section 502(w)(3) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), shall apply beginning on September 30, 2023.

tv_txt: II 115th CONGRESS 2d Session H. R. 5554 IN THE SENATE OF THE UNITED STATES July 17, 2018 Received AN ACT To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.

1. Short title This Act may be cited as the Animal Drug and Animal Generic Drug User Fee Amendments of 2018 . 2. Table of contents; references in Act (a) Table of contents The table of contents for this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents; references in Act. Title I—Fees Relating to Animal Drugs Sec. 101. Short title; finding. Sec. 102. Definitions. Sec. 103. Authority to assess and use animal drug fees. Sec. 104. Reauthorization; reporting requirements. Sec. 105. Savings clause. Sec. 106. Effective date. Sec. 107. Sunset dates. Title II—Fees Relating to Generic Animal Drugs Sec. 201. Short title; finding. Sec. 202. Authority to assess and use generic new animal drug fees. Sec. 203. Reauthorization; reporting requirements. Sec. 204. Savings clause. Sec. 205. Effective date. Sec. 206. Sunset dates. Title III—Miscellaneous Provisions Sec. 301. Electronic submissions. Sec. 302. Index of legally marketed unapproved new animal drugs for minor species. Sec. 303. Misbranded drugs and devices. Sec. 304. Conditional approval of new animal drugs. Sec. 305. Guidance addressing investigation designs. Sec. 306. Food additives intended for use in animal food. (b) References in Act Except as otherwise specified, amendments made by this Act to a section or other provision of law are amendments to such section or other provision of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq.). I Fees Relating to Animal Drugs 101. Short title; finding (a) Short title This title may be cited as the Animal Drug User Fee Amendments of 2018 . (b) Finding Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the animal drug development process and the review of new and supplemental animal drug applications and investigational animal drug submissions as set forth in the goals identified for purposes of part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate as set forth in the Congressional Record. 102. Definitions Section 739 ( 21 U.S.C. 379j–11 ) is amended— (1) by amending paragraph (1) to read as follows: (1) (A) The term animal drug application means— (i) an application for approval of any new animal drug submitted under section 512(b)(1); or (ii) an application for conditional approval of a new animal drug submitted under section 571. (B) Such term does not include either a new animal drug application submitted under section 512(b)(2) or a supplemental animal drug application. ; and (2) in paragraph (8), by adding at the end the following: (I) The activities necessary for implementation of the United States and European Union Good Manufacturing Practice Mutual Inspection Agreement with respect to animal drug products subject to review, including implementation activities prior to and following product approval. . 103. Authority to assess and use animal drug fees (a) Fee revenue amounts Section 740(b) ( 21 U.S.C. 379j–12(b) ) is amended— (1) in paragraph (1)— (A) in subparagraph (A)— (i) by striking 2014 and inserting 2019 ; and (ii) by striking $23,600,000 and inserting $30,331,240 ; and (B) in subparagraph (B)— (i) by striking 2015 through 2018 and inserting 2020 through 2023 ; and (ii) by striking $21,600,000 and inserting $29,931,240 ; and (2) in paragraph (2), in the matter preceding subparagraph (A), by striking determined and inserting established . (b) Annual fee setting; adjustments (1) Inflation adjustment Section 740(c)(2) ( 21 U.S.C. 379j–12(c)(2) ) is amended— (A) in the matter preceding subparagraph (A)— (i) by striking For fiscal year 2015 and inserting (A) For fiscal year 2020 ; and (ii) by inserting multiplying such revenue amounts by before an amount ; (B) by redesignating subparagraphs (A), (B), and (C) as clauses (i), (ii), and (iii), respectively; (C) by striking the flush text at the end; and (D) by adding at the end the following new subparagraph: (B) Compounded basis The adjustment made each fiscal year after fiscal year 2020 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year. . (2) Workload adjustments Paragraph (3) of section 740(c) ( 21 U.S.C. 379j–12(c) ) is amended to read as follows: (3) Workload adjustments (A) In general For fiscal year 2020 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for such fiscal year to reflect changes in the workload of the Secretary for the process for the review of animal drug applications, subject to subparagraphs (B) and (C). With respect to such adjustment— (i) such adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of animal drug applications, supplemental animal drug applications for which data with respect to safety or effectiveness are required, manufacturing supplemental animal drug applications, investigational animal drug study submissions, and investigational animal drug protocol submissions submitted to the Secretary; and (ii) the Secretary shall publish in the Federal Register the fees resulting from such adjustment and the supporting methodologies. (B) Reduction of workload-based increase by amount of certain excess collections For each of fiscal years 2021 through 2023, if application of the workload adjustment under subparagraph (A) increases the fee revenue amounts otherwise established for the fiscal year under subsection (b), as adjusted for inflation under paragraph (2), such fee revenue increase shall be reduced by the amount of any excess collections, as described in subsection (g)(4), for the second preceding fiscal year, up to the amount of such fee revenue increase. (C) Rule of application Under no circumstances shall the workload adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established under subsection (b), as adjusted for inflation under paragraph (2). . (3) Final year adjustment Section 740(c)(4) ( 21 U.S.C. 379j–12(c)(4) ) is amended— (A) by striking 2018 each place it appears and inserting 2023 ; and (B) by striking 2019 and inserting 2024 . (c) Exemptions from fees Section 740(d) ( 21 U.S.C. 379j–12(d) ) is amended— (1) in the subsection heading, by inserting ; exemptions from fees after reduction ; (2) by striking the heading of paragraph (1) and inserting Waiver or reduction ; and (3) by adding at the end the following: (4) Exemptions from fees (A) Certain labeling supplements To add number of approved application Fees under this section shall not apply with respect to any person who— (i) not later than September 30, 2023, submits a supplemental animal drug application relating to a new animal drug application approved under section 512, solely to add the new animal drug application number to the labeling of the drug in the manner specified in section 502(w)(3); and (ii) otherwise would be subject to fees under this section solely on the basis of such supplemental application. (B) Certain animal drug applications Fees under paragraphs (2), (3), and (4) of subsection (a) shall not apply with respect to any person who is the named applicant or sponsor of an animal drug application, supplemental animal drug application, or investigational animal drug submission if such application or submission involves the intentional genomic alteration of an animal that is intended to produce a drug, device, or biological product subject to fees under section 736, 738, 744B, or 744H. . (d) Crediting and availability of fees (1) Authorization of appropriations Section 740(g)(3) ( 21 U.S.C. 379j–12(g)(3) ) is amended— (A) by striking 2014 through 2018 and inserting 2019 through 2023 ; (B) by striking determined and inserting established ; and (C) by striking paragraph (4) and inserting paragraph (5) . (2) Excess collections Section 740(g) ( 21 U.S.C. 379j–12(g) ) is amended by striking paragraph (4) and inserting the following: (4) Excess collections If the sum total of fees collected under this section for a fiscal year exceeds the amount of fees authorized to be appropriated for such year under paragraph (3), the excess collections shall be credited to the appropriations account of the Food and Drug Administration as provided in paragraph (1). (5) Recovery of collection shortfalls (A) In general Subject to subparagraph (B)— (i) for fiscal year 2021, the amount of fees otherwise authorized to be collected under this section shall be increased by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2019 falls below the amount of fees authorized for fiscal year 2019 under paragraph (3); (ii) for fiscal year 2022, the amount of fees otherwise authorized to be collected under this section shall be increased by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2020 falls below the amount of fees authorized for fiscal year 2020 under paragraph (3); and (iii) for fiscal year 2023, the amount of fees otherwise authorized to be collected under this section shall be increased by the cumulative amount, if any, by which the amount collected under this section and appropriated for fiscal years 2021 and 2022 (including estimated collections for fiscal year 2022) falls below the cumulative amount of fees authorized for such fiscal years under paragraph (3). (B) Reduction of shortfall-based fee increase by prior year excess collections (i) In general Subject to clause (ii), the Secretary shall, in such manner as the Secretary determines appropriate, reduce any fee increase otherwise applicable for a fiscal year under subparagraph (A) by the amount of any excess collections under this section for preceding fiscal years (after fiscal year 2018). (ii) Workload-based fee accounting In applying clause (i), the Secretary shall account for the reduction of workload-based fee revenue increases by excess collections under subsection (c)(3)(B), in such manner as needed to provide that no portion of any excess collections described in clause (i) is applied for purposes of reducing fee increases under both such subsection (c)(3)(B) and this paragraph. (C) Rule of application Under no circumstances shall adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established in subsection (b), as adjusted or otherwise affected under subsection (c). . 104. Reauthorization; reporting requirements Section 740A ( 21 U.S.C. 379j–13 ) is amended— (1) in subsection (a), by striking 2013 and inserting 2018 ; (2) by striking 2014 each place it appears in subsections (a) and (b) and inserting 2019 ; and (3) in subsection (d), by striking 2018 each place it appears and inserting 2023 . 105. Savings clause Notwithstanding the amendments made by this title, part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–11 et seq.), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after October 1, 2013, but before October 1, 2018, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019. 106. Effective date The amendments made by this title shall take effect on October 1, 2018, or the date of the enactment of this Act, whichever is later, except that fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as amended by this title, shall be assessed for animal drug applications and supplemental animal drug applications received on or after October 1, 2018, regardless of the date of the enactment of this Act. 107. Sunset dates (a) Authorization Section 740 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–12 ) shall cease to be effective October 1, 2023. (b) Reporting requirements Section 740A of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–13 ) shall cease to be effective January 31, 2024. (c) Previous sunset provision Effective October 1, 2018, subsections (a) and (b) of section 107 of the Animal Drug User Fee Amendments of 2013 ( Public Law 113–14 ) are repealed. II Fees Relating to Generic Animal Drugs 201. Short title; finding (a) Short title This title may be cited as the Animal Generic Drug User Fee Amendments of 2018 . (b) Finding Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the generic new animal drug development process and the review of abbreviated applications for generic new animal drugs, supplemental abbreviated applications for generic new animal drugs, and investigational submissions for generic new animal drugs as set forth in the goals identified for purposes of part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor and Pensions of the Senate as set forth in the Congressional Record. 202. Authority to assess and use generic new animal drug fees (a) Fee revenue amounts Subsection (b) of section 741 ( 21 U.S.C. 379j–21 ) is amended to read as follows: (b) Fee revenue amounts (1) In general Subject to subsections (c), (d), (f), and (g), for each of fiscal years 2019 through 2023, the fees required under subsection (a) shall be established to generate a total revenue amount of $18,336,340. (2) Types of fees Of the total revenue amount established for a fiscal year under paragraph (1)— (A) 25 percent shall be derived from fees under subsection (a)(1) (relating to abbreviated applications for a generic new animal drug); (B) 37.5 percent shall be derived from fees under subsection (a)(2) (relating to generic new animal drug products); and (C) 37.5 percent shall be derived from fees under subsection (a)(3) (relating to generic new animal drug sponsors). . (b) Annual fee setting; adjustments (1) Inflation adjustment Section 741(c) ( 21 U.S.C. 379j–21(c) ) is amended— (A) by redesignating paragraphs (2) through (4) as paragraphs (3) through (5), respectively; and (B) by inserting after paragraph (1) the following: (2) Inflation adjustment (A) In general For fiscal year 2020 and subsequent fiscal years, the revenue amounts established under subsection (b) shall be adjusted by the Secretary by notice, published in the Federal Register, for a fiscal year, by multiplying such revenue amounts by an amount equal to the sum of— (i) one; (ii) the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 of the preceding 4 fiscal years for which data are available, multiplied by the average proportion of personnel compensation and benefits costs to total Food and Drug Administration costs for the first 3 of the preceding 4 fiscal years for which data are available; and (iii) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; not seasonally adjusted; all items less food and energy; annual index) for the first 3 of the preceding 4 years for which data are available multiplied by the average proportion of all costs other than personnel compensation and benefits costs to total Food and Drug Administration costs for the first 3 of the preceding 4 fiscal years for which data are available. (B) Compounded basis The adjustment made each fiscal year after fiscal year 2020 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year. . (2) Workload adjustments Paragraph (3) of section 741(c) ( 21 U.S.C. 379j–21(c) ), as redesignated, is amended to read as follows: (3) Workload adjustments (A) In general For fiscal year 2020 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for each such fiscal year to reflect changes in the workload of the Secretary for the process for the review of abbreviated applications for generic new animal drugs, subject to subparagraphs (B) and (C). With respect to such adjustment— (i) this adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of abbreviated applications for generic new animal drugs, manufacturing supplemental abbreviated applications for generic new animal drugs, investigational generic new animal drug study submissions, and investigational generic new animal drug protocol submissions submitted to the Secretary; and (ii) the Secretary shall publish in the Federal Register the fees resulting from this adjustment and the supporting methodologies. (B) Reduction of workload-based increase by amount of certain excess collections For each of fiscal years 2021 through 2023, if application of the workload adjustment under subparagraph (A) increases the fee revenue amounts otherwise established for the fiscal year under subsection (b), as adjusted for inflation under paragraph (2), such fee revenue increase shall be reduced by the amount of any excess collections, as described in subsection (g)(4), for the second preceding fiscal year, up to the amount of such fee revenue increase. (C) Rule of application Under no circumstances shall workload adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established under subsection (b), as adjusted for inflation under paragraph (2). . (3) Final year adjustment Paragraph (4) of section 741(c) ( 21 U.S.C. 379j–21(c) ), as redesignated, is amended by— (A) striking 2018 each place it appears and inserting 2023 ; and (B) striking 2019 and inserting 2024 . (c) Fee waiver or reduction; exemption from fees Subsection (d) of section 741 ( 21 U.S.C. 379j–21 ) is amended to read as follows: (d) Fee waiver or reduction; exemption from fees (1) Fee waiver or reduction The Secretary shall grant a waiver from or a reduction of one or more fees assessed under subsection (a) where the Secretary finds that the generic new animal drug is intended solely to provide for a minor use or minor species indication. (2) Exemption from fees Fees under this section shall not apply with respect to any person who— (A) not later than September 30, 2023, submits a supplemental abbreviated application for a generic new animal drug approved under section 512, solely to add the application number to the labeling of the drug in the manner specified in section 502(w)(3); and (B) otherwise would be subject to fees under this section solely on the basis of such supplemental abbreviated application. . (d) Crediting and availability of fees Section 741(g) ( 21 U.S.C. 379j–21 ) is amended by striking paragraph (3) and inserting the following paragraphs: (3) Authorization of appropriations For each of the fiscal years 2019 through 2023, there is authorized to be appropriated for fees under this section an amount equal to the total revenue amount established under subsection (b) for the fiscal year, as adjusted or otherwise affected under subsection (c). (4) Excess collections If the sum total of fees collected under this section for a fiscal year exceeds the amount of fees authorized to be appropriated for such year under paragraph (3), the excess collections shall be credited to the appropriations account of the Food and Drug Administration as provided in paragraph (1). . 203. Reauthorization; reporting requirements Section 742 ( 21 U.S.C. 379j–22 ) is amended— (1) in subsection (a), by striking 2013 and inserting 2018 ; (2) in subsection (b), by striking Committee on Health, Education, Labor, and Pensions and inserting the Committee on Health, Education, Labor and Pensions ; (3) by striking 2014 each place it appears in subsections (a) and (b) and inserting 2019 ; and (4) in subsection (d), by striking 2018 each place it appears and inserting 2023 . 204. Savings clause Notwithstanding the amendments made by this title, part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 et seq.), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug (as defined in such part as of such day) that on or after October 1, 2013, but before October 1, 2018, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019. 205. Effective date The amendments made by this title shall take effect on October 1, 2018, or the date of the enactment of this Act, whichever is later, except that fees under part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as amended by this title, shall be assessed for abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug received on or after October 1, 2018, regardless of the date of enactment of this Act. 206. Sunset dates (a) Authorization Section 741 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 ) shall cease to be effective October 1, 2023. (b) Reporting requirements Section 742 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–22 ) shall cease to be effective January 31, 2024. (c) Previous sunset provision Effective October 1, 2018, subsections (a) and (b) of section 206 of the Animal Generic Drug User Fee Amendments of 2013 ( Public Law 113–14 ) are repealed. III Miscellaneous Provisions 301. Electronic submissions (a) New animal drug applications and abbreviated applications for a generic new animal drug Section 512(b) ( 21 U.S.C. 360b(b) ) is amended by adding at the end the following: (4) Beginning on October 1, 2018, all applications or submissions pursuant to this subsection shall be submitted by electronic means in such format as the Secretary may require. . (b) Conditional approval of new animal drugs for minor use and minor species Section 571(a) ( 21 U.S.C. 360ccc(a) ) is amended by adding at the end the following: (4) Beginning on October 1, 2018, all applications or submissions pursuant to this subsection shall be submitted by electronic means in such format as the Secretary may require. . 302. Index of legally marketed unapproved new animal drugs for minor species Effective on October 1, 2018, section 572(h) ( 21 U.S.C. 360ccc–1(h) ) is amended— (1) by amending paragraph (1) to read as follows: (1) LEGAL STATUS—In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the Food and Drug Administration. THIS PRODUCT IS INDEXED—MIF # (followed by the applicable minor species index file number and a period) Extra-label use is prohibited. ; ; and (2) in paragraph (2), by striking other animals and inserting food-producing animals . 303. Misbranded drugs and devices (a) In general Section 502(w) ( 21 U.S.C. 352(w) ) is amended— (1) in subparagraph (1), by striking ; or and inserting ; ; (2) in subparagraph (2), by striking the period and inserting ; or ; and (3) by adding at the end the following: (3) for which an application has been approved under section 512 and the labeling of such drug does not include the application number in the format: Approved by FDA under (A)NADA # xxx–xxx , except that this subparagraph shall not apply to representative labeling required under section 514.1(b)(3)(v)(b) of title 21, Code of Federal Regulations (or any successor regulation) for animal feed bearing or containing a new animal drug. . (b) Applicability Section 502(w)(3) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), shall apply beginning on September 30, 2023. 304. Conditional approval of new animal drugs (a) In general Section 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ccc ) is amended— (1) in the section heading, by striking species and inserting species and certain new animal drugs ; (2) in subsection (a)— (A) by amending paragraph (1) to read as follows: (1) (A) Except as provided in paragraph (3), any person may file with the Secretary an application for conditional approval of— (i) a new animal drug intended for a minor use or a minor species; or (ii) a new animal drug not intended for a minor use or minor species— (I) that is intended to treat a serious or life-threatening disease or condition or addresses an unmet animal or human health need; and (II) for which the Secretary determines that a demonstration of effectiveness would require a complex or particularly difficult study or studies. (B) The Secretary shall, not later than September 30, 2019, issue guidance or regulations further clarifying the criteria specified in subparagraph (A)(ii). (C) An application under this paragraph shall comply in all respects with the provisions of section 512 except for subsections (a)(4), (b)(2), (c)(1), (c)(2), (c)(3), (d)(1), (e), (h), and (n) of such section unless otherwise stated in this section, and any additional provisions of this section. (D) New animal drugs for which conditional approval is sought under this section are subject to the same safety standards that would be applied to new animal drugs under section 512(d) (including, for antimicrobial new animal drugs, with respect to antimicrobial resistance). ; and (B) in paragraph (3)— (i) in subparagraph (B), by striking , or and inserting ; or ; (ii) by redesignating subparagraphs (A), (B), and (C) as clauses (i), (ii), and (iii), respectively; (iii) by striking A person may not file and inserting (A) A person may not file ; and (iv) by adding at the end the following new subparagraph: (B) A person may not file an application under paragraph (1)(A)(ii) if the application seeks conditional approval of a new animal drug that contains an antimicrobial active ingredient. ; (3) in subsection (f)— (A) in paragraph (1), in the matter preceding subparagraph (A), by inserting for the conditionally approved use after shall ; and (B) in paragraph (2)— (i) by striking An intended use and inserting The Secretary shall, through regulation or guidance, determine under what conditions an intended use ; and (ii) by striking shall not and inserting may ; and (4) by adding at the end the following new subsection: (k) Sunset (1) The Secretary’s authority to grant conditional approval of new animal drugs not intended for a minor use or minor species pursuant to subsection (a)(1)(A)(ii) terminates on October 1, 2028. (2) The Secretary— (A) may not accept any new applications for such conditional approval pursuant to subsection (a)(1)(A)(ii) on or after such date; and (B) may continue all activities under this section with respect to drugs that were conditionally approved pursuant to (a)(1)(A)(ii) prior to such date. (3) The Secretary may, until October 1, 2032, accept applications for approval under 512 of drugs conditionally approved pursuant to (a)(1)(A)(ii). . (b) Exception from fees in case of certain previously submitted applications for conditional approval Section 740(a)(1)(C) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–12(a)(1)(C) ) is amended— (1) in the caption by striking Exception and inserting Exceptions ; (2) by striking If an animal drug and inserting the following: (i) If an animal drug ; and (3) by inserting after clause (i), as so designated, the following new clause: (ii) Beginning with fiscal year 2019, in the case of an animal drug application submitted by a person under section 512(b)(1), where such person (or their licensor, assignor, or predecessor-in-interest) previously submitted an application for conditional approval under section 571 for the same product and paid the applicable fee under subparagraph (A), the application under section 512(b)(1) shall not be subject to a fee under subparagraph (A) if submitted within the timeframe specified in section 571(h). . (c) Report on incorporating veterinary oversight Not later than September 30, 2019, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall submit a report to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor and Pensions of the Senate identifying how the Food and Drug Administration will incorporate veterinary oversight for all approved medically important antimicrobial drugs administered to animals that are not yet subject to veterinary oversight. Such report shall address requirements related to revisions of labeling to reflect that medically important antimicrobial drugs administered to animals shall be subject to veterinary oversight. (d) GAO study of conditional approval programs (1) Study The Comptroller General of the United States (referred to in this section as the Comptroller General ) shall conduct a study on the effectiveness and overall impact of the conditional approval pathway under section 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ccc ). (2) Issuance of report Not later than January 1, 2026, the Comptroller General shall submit to the Committee on Health, Education, Labor and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing the results of the study under paragraph (1). (3) Contents of reports The report submitted under paragraph (2) shall address— (A) for each drug for which a conditional approval has been awarded since October 1, 2018— (i) whether the drug was granted conditional approval pursuant to clause (i) or (ii) of section 571(a)(1)(A) of the Federal Food, Drug, and Cosmetic Act, as amended by subsection (a); (ii) whether the drug was dual labeled during its conditional approval; (iii) the indications for which the drug was granted conditional approval under section 571 of such Act ( 21 U.S.C. 360ccc ) and whether the drug was approved or not approved under section 512 of such Act ( 21 U.S.C. 360b ); (iv) the number of years the drug was so conditionally approved and a description of the complexity of the investigation to demonstrate the drug’s effectiveness; (v) whether, and to what extent, the conditional approval pathway under such section 571 ( 21 U.S.C. 360ccc ) impacted the sponsor’s decision to develop the drug or seek approval of the drug under section 512 of such Act ( 21 U.S.C. 360b ); (vi) whether, and to what extent, conditional approval pursuant to clause (ii) of section 571(a)(1)(A) of such Act ( 21 U.S.C. 360b(a)(1)(A) ) addressed a serious or life-threatening condition; and (vii) whether, and to what extent, conditional approval pursuant to clause (ii) of section 571(a)(1)(A) of such Act ( 21 U.S.C. 360b(a)(1)(A) ) addressed an unmet animal or human health need, and whether before such conditional approval there were available therapies for the disease or condition involved; (B) an analysis of the conditional approval program under section 571 of such Act ( 21 U.S.C. 360ccc ), including— (i) the resources used by the Food and Drug Administration in reviewing applications for conditional approval of drugs pursuant to such program and renewal of such conditional approval, including the effects of the program on the Food and Drug Administration’s review of animal drugs for which conditional approval is not used; (ii) whether any improvements to the program under section 512 of such Act ( 21 U.S.C. 360b ) are necessary to incentivize the development of animal drugs that would likely not otherwise be developed, or developed in as timely a manner, to address— (I) serious or life-threatening conditions; and (II) an unmet animal or human health need; and (iii) whether the conditional approval pathway has resulted in a greater number of animal drugs approved under section 512 of such Act ( 21 U.S.C. 360b ) for serious or life-threatening conditions or unmet animal or human health needs than would have otherwise come to market under the practices and commitments of the Center for Veterinary Medicine of the Food and Drug Administration as such practices and commitments existed as of the day before the date of enactment of this Act; and (C) how the Center for Veterinary Medicine of the Food and Drug Administration has utilized complex adaptive or other novel investigation designs, data from foreign countries, real-world evidence (including ongoing surveillance activities, observational studies, and registry data), biomarkers, or surrogate endpoints— (i) to support the approval of products under section 512 of such Act ( 21 U.S.C. 360b ), including how many such products have been approved since October 1, 2018; and (ii) to support the approval of products under section 512 of such Act ( 21 U.S.C. 360b ) that received conditional approval under section 571 of such Act ( 21 U.S.C. 360ccc ), including how many such products have been approved since October 1, 2018. 305. Guidance addressing investigation designs (a) In general For purposes of assisting sponsors in incorporating complex adaptive and other novel investigation designs, data from foreign countries, real world evidence (including ongoing surveillance activities, observational studies, and registry data), biomarkers, and surrogate endpoints (referred to in this section as elements of investigations ) into proposed clinical investigation protocols and applications for new animal drugs under sections 512 and 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360b ; 360ccc), the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall issue guidance addressing the use of such elements of investigations in the development and regulatory review of such new animal drugs. (b) Contents The guidance under subsection (a) shall address how the Secretary will evaluate the elements of investigations proposed or submitted pursuant to section 512(b)(1)(A) of the Federal Food, Drug, and Cosmetic Act or to meet the commitment under section 571(a)(2)(F) of such Act, and how sponsors of such applications may obtain feedback from the Secretary on technical issues related to such investigations prior to the submission of an application to the Secretary. (c) Meeting Prior to issuing the guidance under subsection (a), the Secretary shall consult with stakeholders, including representatives of regulated industry, consumer groups, academia, veterinarians, and food producers, through a public meeting to be held not later than 1 year after the date of enactment of this Act. (d) Timing The Secretary shall issue a draft guidance under subsection (a) not later than 1 year after the date of the public meeting under subsection (c), and shall finalize such guidance not later than 1 year after the date on which the public comment period on such draft guidance ends. 306. Food additives intended for use in animal food (a) Food additive petitions for animal food Section 409 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 348 ) is amended by adding at the end the following: (k) Food additives intended for use in animal food (1) In taking action on a petition under subsection (c) for, or for recognition of, a food additive intended for use in animal food, the Secretary shall review reports of investigations conducted in foreign countries, provided by the petitioner. (2) Not later than 12 months after the date of enactment of the Animal Drug and Animal Generic Drug Use Fee Amendments of 2018, the Secretary shall post on the internet website of the Food and Drug Administration— (A) the number of petitions for food additives intended for use in animal food filed under subsection (b) that are pending; (B) how long each such petition submitted under subsection (b) has been pending, including such petitions the Secretary has extended under subsection (c)(2); and (C) the number of study protocols that have been pending review for over 50 days, and the number that have received an extension. (3) In the case of a food additive petition intended for use in animal food, the Secretary shall provide information to the petitioner on the required contents of such petition. If the Secretary requires additional studies beyond what the petitioner proposed, the Secretary shall provide the scientific rationale for such requirement. . (b) Ensuring the safety of pet food Section 1002(a) of the Food and Drug Administration Amendments Act of 2007 ( 21 U.S.C. 2102(a) ) is amended— (1) by striking paragraph (1); and (2) by redesignating paragraphs (2) and (3) as paragraphs (1) and (2), respectively. (c) Guidance on pre-Petition consultation process for animal food additives (1) In general Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this subsection as the Secretary ) shall publish draft guidance relating to the voluntary pre-petition consultation process for food additives intended for use in animal food. (2) Contents The guidance under paragraph (1) shall include— (A) the recommended format to submit to the Food and Drug Administration existing data, including any applicable foreign data, for assessment prior to submission of a food additive petition for animal food under section 409(b) of the Federal Food, Drug, and Cosmetic Act; (B) the manner and the number of days by which the Food and Drug Administration intends to review and respond to such existing data, including with respect to providing a scientific rationale for any additional data request; (C) circumstances under which the submission of study protocols is recommended prior to submission of a food additive petition under such section 409(b); (D) the manner in which the Secretary intends to inform the person submitting a study protocol for a food additive if the review of such study protocol will take longer than 50 days; and (E) best practices for communication between the Food and Drug Administration and industry on the development of pre-petition submissions of study protocols and existing data for food additives. (3) Final guidance The guidance under paragraph (1) shall be finalized, withdrawn, or reissued not later than 1 year after the close of the comment period on the draft guidance.

Passed the House of Representatives July 16, 2018. Karen L. Haas, Clerk.

tv_txt: I 115th CONGRESS 2d Session H. R. 5554 IN THE HOUSE OF REPRESENTATIVES AN ACT To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.

1. Short title This Act may be cited as the Animal Drug and Animal Generic Drug User Fee Amendments of 2018 . 2. Table of contents; references in Act (a) Table of contents The table of contents for this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents; references in Act. Title I—Fees Relating to Animal Drugs Sec. 101. Short title; finding. Sec. 102. Definitions. Sec. 103. Authority to assess and use animal drug fees. Sec. 104. Reauthorization; reporting requirements. Sec. 105. Savings clause. Sec. 106. Effective date. Sec. 107. Sunset dates. Title II—Fees Relating to Generic Animal Drugs Sec. 201. Short title; finding. Sec. 202. Authority to assess and use generic new animal drug fees. Sec. 203. Reauthorization; reporting requirements. Sec. 204. Savings clause. Sec. 205. Effective date. Sec. 206. Sunset dates. Title III—Miscellaneous Provisions Sec. 301. Electronic submissions. Sec. 302. Index of legally marketed unapproved new animal drugs for minor species. Sec. 303. Misbranded drugs and devices. Sec. 304. Conditional approval of new animal drugs. Sec. 305. Guidance addressing investigation designs. Sec. 306. Food additives intended for use in animal food. (b) References in Act Except as otherwise specified, amendments made by this Act to a section or other provision of law are amendments to such section or other provision of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq.). I Fees Relating to Animal Drugs 101. Short title; finding (a) Short title This title may be cited as the Animal Drug User Fee Amendments of 2018 . (b) Finding Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the animal drug development process and the review of new and supplemental animal drug applications and investigational animal drug submissions as set forth in the goals identified for purposes of part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate as set forth in the Congressional Record. 102. Definitions Section 739 ( 21 U.S.C. 379j–11 ) is amended— (1) by amending paragraph (1) to read as follows: (1) (A) The term animal drug application means— (i) an application for approval of any new animal drug submitted under section 512(b)(1); or (ii) an application for conditional approval of a new animal drug submitted under section 571. (B) Such term does not include either a new animal drug application submitted under section 512(b)(2) or a supplemental animal drug application. ; and (2) in paragraph (8), by adding at the end the following: (I) The activities necessary for implementation of the United States and European Union Good Manufacturing Practice Mutual Inspection Agreement with respect to animal drug products subject to review, including implementation activities prior to and following product approval. . 103. Authority to assess and use animal drug fees (a) Fee revenue amounts Section 740(b) ( 21 U.S.C. 379j–12(b) ) is amended— (1) in paragraph (1)— (A) in subparagraph (A)— (i) by striking 2014 and inserting 2019 ; and (ii) by striking $23,600,000 and inserting $30,331,240 ; and (B) in subparagraph (B)— (i) by striking 2015 through 2018 and inserting 2020 through 2023 ; and (ii) by striking $21,600,000 and inserting $29,931,240 ; and (2) in paragraph (2), in the matter preceding subparagraph (A), by striking determined and inserting established . (b) Annual fee setting; adjustments (1) Inflation adjustment Section 740(c)(2) ( 21 U.S.C. 379j–12(c)(2) ) is amended— (A) in the matter preceding subparagraph (A)— (i) by striking For fiscal year 2015 and inserting (A) For fiscal year 2020 ; and (ii) by inserting multiplying such revenue amounts by before an amount ; (B) by redesignating subparagraphs (A), (B), and (C) as clauses (i), (ii), and (iii), respectively; (C) by striking the flush text at the end; and (D) by adding at the end the following new subparagraph: (B) Compounded basis The adjustment made each fiscal year after fiscal year 2020 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year. . (2) Workload adjustments Paragraph (3) of section 740(c) ( 21 U.S.C. 379j–12(c) ) is amended to read as follows: (3) Workload adjustments (A) In general For fiscal year 2020 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for such fiscal year to reflect changes in the workload of the Secretary for the process for the review of animal drug applications, subject to subparagraphs (B) and (C). With respect to such adjustment— (i) such adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of animal drug applications, supplemental animal drug applications for which data with respect to safety or effectiveness are required, manufacturing supplemental animal drug applications, investigational animal drug study submissions, and investigational animal drug protocol submissions submitted to the Secretary; and (ii) the Secretary shall publish in the Federal Register the fees resulting from such adjustment and the supporting methodologies. (B) Reduction of workload-based increase by amount of certain excess collections For each of fiscal years 2021 through 2023, if application of the workload adjustment under subparagraph (A) increases the fee revenue amounts otherwise established for the fiscal year under subsection (b), as adjusted for inflation under paragraph (2), such fee revenue increase shall be reduced by the amount of any excess collections, as described in subsection (g)(4), for the second preceding fiscal year, up to the amount of such fee revenue increase. (C) Rule of application Under no circumstances shall the workload adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established under subsection (b), as adjusted for inflation under paragraph (2). . (3) Final year adjustment Section 740(c)(4) ( 21 U.S.C. 379j–12(c)(4) ) is amended— (A) by striking 2018 each place it appears and inserting 2023 ; and (B) by striking 2019 and inserting 2024 . (c) Exemptions from fees Section 740(d) ( 21 U.S.C. 379j–12(d) ) is amended— (1) in the subsection heading, by inserting ; exemptions from fees after reduction ; (2) by striking the heading of paragraph (1) and inserting Waiver or reduction ; and (3) by adding at the end the following: (4) Exemptions from fees (A) Certain labeling supplements To add number of approved application Fees under this section shall not apply with respect to any person who— (i) not later than September 30, 2023, submits a supplemental animal drug application relating to a new animal drug application approved under section 512, solely to add the new animal drug application number to the labeling of the drug in the manner specified in section 502(w)(3); and (ii) otherwise would be subject to fees under this section solely on the basis of such supplemental application. (B) Certain animal drug applications Fees under paragraphs (2), (3), and (4) of subsection (a) shall not apply with respect to any person who is the named applicant or sponsor of an animal drug application, supplemental animal drug application, or investigational animal drug submission if such application or submission involves the intentional genomic alteration of an animal that is intended to produce a drug, device, or biological product subject to fees under section 736, 738, 744B, or 744H. . (d) Crediting and availability of fees (1) Authorization of appropriations Section 740(g)(3) ( 21 U.S.C. 379j–12(g)(3) ) is amended— (A) by striking 2014 through 2018 and inserting 2019 through 2023 ; (B) by striking determined and inserting established ; and (C) by striking paragraph (4) and inserting paragraph (5) . (2) Excess collections Section 740(g) ( 21 U.S.C. 379j–12(g) ) is amended by striking paragraph (4) and inserting the following: (4) Excess collections If the sum total of fees collected under this section for a fiscal year exceeds the amount of fees authorized to be appropriated for such year under paragraph (3), the excess collections shall be credited to the appropriations account of the Food and Drug Administration as provided in paragraph (1). (5) Recovery of collection shortfalls (A) In general Subject to subparagraph (B)— (i) for fiscal year 2021, the amount of fees otherwise authorized to be collected under this section shall be increased by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2019 falls below the amount of fees authorized for fiscal year 2019 under paragraph (3); (ii) for fiscal year 2022, the amount of fees otherwise authorized to be collected under this section shall be increased by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2020 falls below the amount of fees authorized for fiscal year 2020 under paragraph (3); and (iii) for fiscal year 2023, the amount of fees otherwise authorized to be collected under this section shall be increased by the cumulative amount, if any, by which the amount collected under this section and appropriated for fiscal years 2021 and 2022 (including estimated collections for fiscal year 2022) falls below the cumulative amount of fees authorized for such fiscal years under paragraph (3). (B) Reduction of shortfall-based fee increase by prior year excess collections (i) In general Subject to clause (ii), the Secretary shall, in such manner as the Secretary determines appropriate, reduce any fee increase otherwise applicable for a fiscal year under subparagraph (A) by the amount of any excess collections under this section for preceding fiscal years (after fiscal year 2018). (ii) Workload-based fee accounting In applying clause (i), the Secretary shall account for the reduction of workload-based fee revenue increases by excess collections under subsection (c)(3)(B), in such manner as needed to provide that no portion of any excess collections described in clause (i) is applied for purposes of reducing fee increases under both such subsection (c)(3)(B) and this paragraph. (C) Rule of application Under no circumstances shall adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established in subsection (b), as adjusted or otherwise affected under subsection (c). . 104. Reauthorization; reporting requirements Section 740A ( 21 U.S.C. 379j–13 ) is amended— (1) in subsection (a), by striking 2013 and inserting 2018 ; (2) by striking 2014 each place it appears in subsections (a) and (b) and inserting 2019 ; and (3) in subsection (d), by striking 2018 each place it appears and inserting 2023 . 105. Savings clause Notwithstanding the amendments made by this title, part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–11 et seq.), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after October 1, 2013, but before October 1, 2018, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019. 106. Effective date The amendments made by this title shall take effect on October 1, 2018, or the date of the enactment of this Act, whichever is later, except that fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as amended by this title, shall be assessed for animal drug applications and supplemental animal drug applications received on or after October 1, 2018, regardless of the date of the enactment of this Act. 107. Sunset dates (a) Authorization Section 740 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–12 ) shall cease to be effective October 1, 2023. (b) Reporting requirements Section 740A of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–13 ) shall cease to be effective January 31, 2024. (c) Previous sunset provision Effective October 1, 2018, subsections (a) and (b) of section 107 of the Animal Drug User Fee Amendments of 2013 ( Public Law 113–14 ) are repealed. II Fees Relating to Generic Animal Drugs 201. Short title; finding (a) Short title This title may be cited as the Animal Generic Drug User Fee Amendments of 2018 . (b) Finding Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the generic new animal drug development process and the review of abbreviated applications for generic new animal drugs, supplemental abbreviated applications for generic new animal drugs, and investigational submissions for generic new animal drugs as set forth in the goals identified for purposes of part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor and Pensions of the Senate as set forth in the Congressional Record. 202. Authority to assess and use generic new animal drug fees (a) Fee revenue amounts Subsection (b) of section 741 ( 21 U.S.C. 379j–21 ) is amended to read as follows: (b) Fee revenue amounts (1) In general Subject to subsections (c), (d), (f), and (g), for each of fiscal years 2019 through 2023, the fees required under subsection (a) shall be established to generate a total revenue amount of $18,336,340. (2) Types of fees Of the total revenue amount established for a fiscal year under paragraph (1)— (A) 25 percent shall be derived from fees under subsection (a)(1) (relating to abbreviated applications for a generic new animal drug); (B) 37.5 percent shall be derived from fees under subsection (a)(2) (relating to generic new animal drug products); and (C) 37.5 percent shall be derived from fees under subsection (a)(3) (relating to generic new animal drug sponsors). . (b) Annual fee setting; adjustments (1) Inflation adjustment Section 741(c) ( 21 U.S.C. 379j–21(c) ) is amended— (A) by redesignating paragraphs (2) through (4) as paragraphs (3) through (5), respectively; and (B) by inserting after paragraph (1) the following: (2) Inflation adjustment (A) In general For fiscal year 2020 and subsequent fiscal years, the revenue amounts established under subsection (b) shall be adjusted by the Secretary by notice, published in the Federal Register, for a fiscal year, by multiplying such revenue amounts by an amount equal to the sum of— (i) one; (ii) the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 of the preceding 4 fiscal years for which data are available, multiplied by the average proportion of personnel compensation and benefits costs to total Food and Drug Administration costs for the first 3 of the preceding 4 fiscal years for which data are available; and (iii) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; not seasonally adjusted; all items less food and energy; annual index) for the first 3 of the preceding 4 years for which data are available multiplied by the average proportion of all costs other than personnel compensation and benefits costs to total Food and Drug Administration costs for the first 3 of the preceding 4 fiscal years for which data are available. (B) Compounded basis The adjustment made each fiscal year after fiscal year 2020 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year. . (2) Workload adjustments Paragraph (3) of section 741(c) ( 21 U.S.C. 379j–21(c) ), as redesignated, is amended to read as follows: (3) Workload adjustments (A) In general For fiscal year 2020 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for each such fiscal year to reflect changes in the workload of the Secretary for the process for the review of abbreviated applications for generic new animal drugs, subject to subparagraphs (B) and (C). With respect to such adjustment— (i) this adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of abbreviated applications for generic new animal drugs, manufacturing supplemental abbreviated applications for generic new animal drugs, investigational generic new animal drug study submissions, and investigational generic new animal drug protocol submissions submitted to the Secretary; and (ii) the Secretary shall publish in the Federal Register the fees resulting from this adjustment and the supporting methodologies. (B) Reduction of workload-based increase by amount of certain excess collections For each of fiscal years 2021 through 2023, if application of the workload adjustment under subparagraph (A) increases the fee revenue amounts otherwise established for the fiscal year under subsection (b), as adjusted for inflation under paragraph (2), such fee revenue increase shall be reduced by the amount of any excess collections, as described in subsection (g)(4), for the second preceding fiscal year, up to the amount of such fee revenue increase. (C) Rule of application Under no circumstances shall workload adjustments under this paragraph result in fee revenues for a fiscal year that are less than the fee revenues for that fiscal year established under subsection (b), as adjusted for inflation under paragraph (2). . (3) Final year adjustment Paragraph (4) of section 741(c) ( 21 U.S.C. 379j–21(c) ), as redesignated, is amended by— (A) striking 2018 each place it appears and inserting 2023 ; and (B) striking 2019 and inserting 2024 . (c) Fee waiver or reduction; exemption from fees Subsection (d) of section 741 ( 21 U.S.C. 379j–21 ) is amended to read as follows: (d) Fee waiver or reduction; exemption from fees (1) Fee waiver or reduction The Secretary shall grant a waiver from or a reduction of one or more fees assessed under subsection (a) where the Secretary finds that the generic new animal drug is intended solely to provide for a minor use or minor species indication. (2) Exemption from fees Fees under this section shall not apply with respect to any person who— (A) not later than September 30, 2023, submits a supplemental abbreviated application for a generic new animal drug approved under section 512, solely to add the application number to the labeling of the drug in the manner specified in section 502(w)(3); and (B) otherwise would be subject to fees under this section solely on the basis of such supplemental abbreviated application. . (d) Crediting and availability of fees Section 741(g) ( 21 U.S.C. 379j–21 ) is amended by striking paragraph (3) and inserting the following paragraphs: (3) Authorization of appropriations For each of the fiscal years 2019 through 2023, there is authorized to be appropriated for fees under this section an amount equal to the total revenue amount established under subsection (b) for the fiscal year, as adjusted or otherwise affected under subsection (c). (4) Excess collections If the sum total of fees collected under this section for a fiscal year exceeds the amount of fees authorized to be appropriated for such year under paragraph (3), the excess collections shall be credited to the appropriations account of the Food and Drug Administration as provided in paragraph (1). . 203. Reauthorization; reporting requirements Section 742 ( 21 U.S.C. 379j–22 ) is amended— (1) in subsection (a), by striking 2013 and inserting 2018 ; (2) in subsection (b), by striking Committee on Health, Education, Labor, and Pensions and inserting the Committee on Health, Education, Labor and Pensions ; (3) by striking 2014 each place it appears in subsections (a) and (b) and inserting 2019 ; and (4) in subsection (d), by striking 2018 each place it appears and inserting 2023 . 204. Savings clause Notwithstanding the amendments made by this title, part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 et seq.), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug (as defined in such part as of such day) that on or after October 1, 2013, but before October 1, 2018, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019. 205. Effective date The amendments made by this title shall take effect on October 1, 2018, or the date of the enactment of this Act, whichever is later, except that fees under part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as amended by this title, shall be assessed for abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug received on or after October 1, 2018, regardless of the date of enactment of this Act. 206. Sunset dates (a) Authorization Section 741 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21 ) shall cease to be effective October 1, 2023. (b) Reporting requirements Section 742 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–22 ) shall cease to be effective January 31, 2024. (c) Previous sunset provision Effective October 1, 2018, subsections (a) and (b) of section 206 of the Animal Generic Drug User Fee Amendments of 2013 ( Public Law 113–14 ) are repealed. III Miscellaneous Provisions 301. Electronic submissions (a) New animal drug applications and abbreviated applications for a generic new animal drug Section 512(b) ( 21 U.S.C. 360b(b) ) is amended by adding at the end the following: (4) Beginning on October 1, 2018, all applications or submissions pursuant to this subsection shall be submitted by electronic means in such format as the Secretary may require. . (b) Conditional approval of new animal drugs for minor use and minor species Section 571(a) ( 21 U.S.C. 360ccc(a) ) is amended by adding at the end the following: (4) Beginning on October 1, 2018, all applications or submissions pursuant to this subsection shall be submitted by electronic means in such format as the Secretary may require. . 302. Index of legally marketed unapproved new animal drugs for minor species Effective on October 1, 2018, section 572(h) ( 21 U.S.C. 360ccc–1(h) ) is amended— (1) by amending paragraph (1) to read as follows: (1) LEGAL STATUS—In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the Food and Drug Administration. THIS PRODUCT IS INDEXED—MIF # (followed by the applicable minor species index file number and a period) Extra-label use is prohibited. ; ; and (2) in paragraph (2), by striking other animals and inserting food-producing animals . 303. Misbranded drugs and devices (a) In general Section 502(w) ( 21 U.S.C. 352(w) ) is amended— (1) in subparagraph (1), by striking ; or and inserting ; ; (2) in subparagraph (2), by striking the period and inserting ; or ; and (3) by adding at the end the following: (3) for which an application has been approved under section 512 and the labeling of such drug does not include the application number in the format: Approved by FDA under (A)NADA # xxx–xxx , except that this subparagraph shall not apply to representative labeling required under section 514.1(b)(3)(v)(b) of title 21, Code of Federal Regulations (or any successor regulation) for animal feed bearing or containing a new animal drug. . (b) Applicability Section 502(w)(3) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), shall apply beginning on September 30, 2023. 304. Conditional approval of new animal drugs (a) In general Section 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ccc ) is amended— (1) in the section heading, by striking species and inserting species and certain new animal drugs ; (2) in subsection (a)— (A) by amending paragraph (1) to read as follows: (1) (A) Except as provided in paragraph (3), any person may file with the Secretary an application for conditional approval of— (i) a new animal drug intended for a minor use or a minor species; or (ii) a new animal drug not intended for a minor use or minor species— (I) that is intended to treat a serious or life-threatening disease or condition or addresses an unmet animal or human health need; and (II) for which the Secretary determines that a demonstration of effectiveness would require a complex or particularly difficult study or studies. (B) The Secretary shall, not later than September 30, 2019, issue guidance or regulations further clarifying the criteria specified in subparagraph (A)(ii). (C) An application under this paragraph shall comply in all respects with the provisions of section 512 except for subsections (a)(4), (b)(2), (c)(1), (c)(2), (c)(3), (d)(1), (e), (h), and (n) of such section unless otherwise stated in this section, and any additional provisions of this section. (D) New animal drugs for which conditional approval is sought under this section are subject to the same safety standards that would be applied to new animal drugs under section 512(d) (including, for antimicrobial new animal drugs, with respect to antimicrobial resistance). ; and (B) in paragraph (3)— (i) in subparagraph (B), by striking , or and inserting ; or ; (ii) by redesignating subparagraphs (A), (B), and (C) as clauses (i), (ii), and (iii), respectively; (iii) by striking A person may not file and inserting (A) A person may not file ; and (iv) by adding at the end the following new subparagraph: (B) A person may not file an application under paragraph (1)(A)(ii) if the application seeks conditional approval of a new animal drug that contains an antimicrobial active ingredient. ; (3) in subsection (f)— (A) in paragraph (1), in the matter preceding subparagraph (A), by inserting for the conditionally approved use after shall ; and (B) in paragraph (2)— (i) by striking An intended use and inserting The Secretary shall, through regulation or guidance, determine under what conditions an intended use ; and (ii) by striking shall not and inserting may ; and (4) by adding at the end the following new subsection: (k) Sunset (1) The Secretary’s authority to grant conditional approval of new animal drugs not intended for a minor use or minor species pursuant to subsection (a)(1)(A)(ii) terminates on October 1, 2028. (2) The Secretary— (A) may not accept any new applications for such conditional approval pursuant to subsection (a)(1)(A)(ii) on or after such date; and (B) may continue all activities under this section with respect to drugs that were conditionally approved pursuant to (a)(1)(A)(ii) prior to such date. (3) The Secretary may, until October 1, 2032, accept applications for approval under 512 of drugs conditionally approved pursuant to (a)(1)(A)(ii). . (b) Exception from fees in case of certain previously submitted applications for conditional approval Section 740(a)(1)(C) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–12(a)(1)(C) ) is amended— (1) in the caption by striking Exception and inserting Exceptions ; (2) by striking If an animal drug and inserting the following: (i) If an animal drug ; and (3) by inserting after clause (i), as so designated, the following new clause: (ii) Beginning with fiscal year 2019, in the case of an animal drug application submitted by a person under section 512(b)(1), where such person (or their licensor, assignor, or predecessor-in-interest) previously submitted an application for conditional approval under section 571 for the same product and paid the applicable fee under subparagraph (A), the application under section 512(b)(1) shall not be subject to a fee under subparagraph (A) if submitted within the timeframe specified in section 571(h). . (c) Report on incorporating veterinary oversight Not later than September 30, 2019, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall submit a report to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor and Pensions of the Senate identifying how the Food and Drug Administration will incorporate veterinary oversight for all approved medically important antimicrobial drugs administered to animals that are not yet subject to veterinary oversight. Such report shall address requirements related to revisions of labeling to reflect that medically important antimicrobial drugs administered to animals shall be subject to veterinary oversight. (d) GAO study of conditional approval programs (1) Study The Comptroller General of the United States (referred to in this section as the Comptroller General ) shall conduct a study on the effectiveness and overall impact of the conditional approval pathway under section 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ccc ). (2) Issuance of report Not later than January 1, 2026, the Comptroller General shall submit to the Committee on Health, Education, Labor and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing the results of the study under paragraph (1). (3) Contents of reports The report submitted under paragraph (2) shall address— (A) for each drug for which a conditional approval has been awarded since October 1, 2018— (i) whether the drug was granted conditional approval pursuant to clause (i) or (ii) of section 571(a)(1)(A) of the Federal Food, Drug, and Cosmetic Act, as amended by subsection (a); (ii) whether the drug was dual labeled during its conditional approval; (iii) the indications for which the drug was granted conditional approval under section 571 of such Act ( 21 U.S.C. 360ccc ) and whether the drug was approved or not approved under section 512 of such Act ( 21 U.S.C. 360b ); (iv) the number of years the drug was so conditionally approved and a description of the complexity of the investigation to demonstrate the drug’s effectiveness; (v) whether, and to what extent, the conditional approval pathway under such section 571 ( 21 U.S.C. 360ccc ) impacted the sponsor’s decision to develop the drug or seek approval of the drug under section 512 of such Act ( 21 U.S.C. 360b ); (vi) whether, and to what extent, conditional approval pursuant to clause (ii) of section 571(a)(1)(A) of such Act ( 21 U.S.C. 360b(a)(1)(A) ) addressed a serious or life-threatening condition; and (vii) whether, and to what extent, conditional approval pursuant to clause (ii) of section 571(a)(1)(A) of such Act ( 21 U.S.C. 360b(a)(1)(A) ) addressed an unmet animal or human health need, and whether before such conditional approval there were available therapies for the disease or condition involved; (B) an analysis of the conditional approval program under section 571 of such Act ( 21 U.S.C. 360ccc ), including— (i) the resources used by the Food and Drug Administration in reviewing applications for conditional approval of drugs pursuant to such program and renewal of such conditional approval, including the effects of the program on the Food and Drug Administration’s review of animal drugs for which conditional approval is not used; (ii) whether any improvements to the program under section 512 of such Act ( 21 U.S.C. 360b ) are necessary to incentivize the development of animal drugs that would likely not otherwise be developed, or developed in as timely a manner, to address— (I) serious or life-threatening conditions; and (II) an unmet animal or human health need; and (iii) whether the conditional approval pathway has resulted in a greater number of animal drugs approved under section 512 of such Act ( 21 U.S.C. 360b ) for serious or life-threatening conditions or unmet animal or human health needs than would have otherwise come to market under the practices and commitments of the Center for Veterinary Medicine of the Food and Drug Administration as such practices and commitments existed as of the day before the date of enactment of this Act; and (C) how the Center for Veterinary Medicine of the Food and Drug Administration has utilized complex adaptive or other novel investigation designs, data from foreign countries, real-world evidence (including ongoing surveillance activities, observational studies, and registry data), biomarkers, or surrogate endpoints— (i) to support the approval of products under section 512 of such Act ( 21 U.S.C. 360b ), including how many such products have been approved since October 1, 2018; and (ii) to support the approval of products under section 512 of such Act ( 21 U.S.C. 360b ) that received conditional approval under section 571 of such Act ( 21 U.S.C. 360ccc ), including how many such products have been approved since October 1, 2018. 305. Guidance addressing investigation designs (a) In general For purposes of assisting sponsors in incorporating complex adaptive and other novel investigation designs, data from foreign countries, real world evidence (including ongoing surveillance activities, observational studies, and registry data), biomarkers, and surrogate endpoints (referred to in this section as elements of investigations ) into proposed clinical investigation protocols and applications for new animal drugs under sections 512 and 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360b ; 360ccc), the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall issue guidance addressing the use of such elements of investigations in the development and regulatory review of such new animal drugs. (b) Contents The guidance under subsection (a) shall address how the Secretary will evaluate the elements of investigations proposed or submitted pursuant to section 512(b)(1)(A) of the Federal Food, Drug, and Cosmetic Act or to meet the commitment under section 571(a)(2)(F) of such Act, and how sponsors of such applications may obtain feedback from the Secretary on technical issues related to such investigations prior to the submission of an application to the Secretary. (c) Meeting Prior to issuing the guidance under subsection (a), the Secretary shall consult with stakeholders, including representatives of regulated industry, consumer groups, academia, veterinarians, and food producers, through a public meeting to be held not later than 1 year after the date of enactment of this Act. (d) Timing The Secretary shall issue a draft guidance under subsection (a) not later than 1 year after the date of the public meeting under subsection (c), and shall finalize such guidance not later than 1 year after the date on which the public comment period on such draft guidance ends. 306. Food additives intended for use in animal food (a) Food additive petitions for animal food Section 409 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 348 ) is amended by adding at the end the following: (k) Food additives intended for use in animal food (1) In taking action on a petition under subsection (c) for, or for recognition of, a food additive intended for use in animal food, the Secretary shall review reports of investigations conducted in foreign countries, provided by the petitioner. (2) Not later than 12 months after the date of enactment of the Animal Drug and Animal Generic Drug Use Fee Amendments of 2018, the Secretary shall post on the internet website of the Food and Drug Administration— (A) the number of petitions for food additives intended for use in animal food filed under subsection (b) that are pending; (B) how long each such petition submitted under subsection (b) has been pending, including such petitions the Secretary has extended under subsection (c)(2); and (C) the number of study protocols that have been pending review for over 50 days, and the number that have received an extension. (3) In the case of a food additive petition intended for use in animal food, the Secretary shall provide information to the petitioner on the required contents of such petition. If the Secretary requires additional studies beyond what the petitioner proposed, the Secretary shall provide the scientific rationale for such requirement. . (b) Ensuring the safety of pet food Section 1002(a) of the Food and Drug Administration Amendments Act of 2007 ( 21 U.S.C. 2102(a) ) is amended— (1) by striking paragraph (1); and (2) by redesignating paragraphs (2) and (3) as paragraphs (1) and (2), respectively. (c) Guidance on pre-Petition consultation process for animal food additives (1) In general Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this subsection as the Secretary ) shall publish draft guidance relating to the voluntary pre-petition consultation process for food additives intended for use in animal food. (2) Contents The guidance under paragraph (1) shall include— (A) the recommended format to submit to the Food and Drug Administration existing data, including any applicable foreign data, for assessment prior to submission of a food additive petition for animal food under section 409(b) of the Federal Food, Drug, and Cosmetic Act; (B) the manner and the number of days by which the Food and Drug Administration intends to review and respond to such existing data, including with respect to providing a scientific rationale for any additional data request; (C) circumstances under which the submission of study protocols is recommended prior to submission of a food additive petition under such section 409(b); (D) the manner in which the Secretary intends to inform the person submitting a study protocol for a food additive if the review of such study protocol will take longer than 50 days; and (E) best practices for communication between the Food and Drug Administration and industry on the development of pre-petition submissions of study protocols and existing data for food additives. (3) Final guidance The guidance under paragraph (1) shall be finalized, withdrawn, or reissued not later than 1 year after the close of the comment period on the draft guidance.

Passed the House of Representatives July 16, 2018. Karen L. Haas, Clerk.